−Removed: AND PROCEDURES .
+Added: CONTROLS AND PROCEDURES .
Evaluation of disclosure controls and procedures
−Removed: Our Chief Executive Officer (who is our principal
−Removed: executive officer) and Chief Financial Officer (who is our principal financial officer), conducted an evaluation of the effectiveness
−Removed: of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under
−Removed: the Securities Exchange Act of 1934 (the “Exchange Act”) as of December 31, 2021.
−Removed: As of December 31, 2021, based
−Removed: upon the evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures
−Removed: were effective.
−Removed: Disclosure controls and procedures designed to reasonably ensure that information required to be disclosed in our reports
−Removed: filed under the Exchange Act, such as this report, is recorded, processed, summarized and reported within the time periods specified
−Removed: in the SEC’s rules and forms.
−Removed: Management’s Annual Report on Internal Control over Financial
−Removed: This Annual Report does not include a report of management’s
−Removed: assessment regarding internal control over financial reporting due to a transition period established by the rules of the SEC for newly
−Removed: public companies.
+Added: Our Chief Executive Officer (who is our principal executive officer)
+Added: and Chief Financial Officer (who is our principal financial officer), conducted an evaluation of the effectiveness of the design and operation
+Added: of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange
+Added: Act of 1934 (the “Exchange Act”) as of December 31, 2022.
+Added: As of December 31, 2022, based upon the evaluation, our principal
+Added: executive officer and principal financial officer concluded that our disclosure controls and procedures were effective.
+Added: Disclosure controls
+Added: and procedures designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act,
+Added: such as this report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.
+Added: Management’s Report on Internal Controls
+Added: Over Financial Reporting
+Added: As required by SEC rules and regulations implementing Section 404
+Added: of the Sarbanes-Oxley Act, our management is responsible for establishing and maintaining adequate internal control over financial reporting.
+Added: Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting
+Added: and the preparation of our financial statements for external reporting purposes in accordance with GAAP.
+Added: Our internal control over financial
+Added: reporting includes those policies and procedures that:
+Added: (1) pertain to the maintenance of records that, in reasonable
+Added: detail, accurately and fairly reflect the transactions and dispositions of the assets of our company,
+Added: (2) provide reasonable assurance that transactions are recorded
+Added: as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being
+Added: made only in accordance with authorizations of our management and directors, and
+Added: (3) provide reasonable assurance regarding prevention or timely
+Added: detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.
+Added: Because of its inherent limitations, internal control over financial
+Added: reporting may not prevent or detect errors or misstatements in our financial statements.
+Added: Also, projections of any evaluation of effectiveness
+Added: to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or
+Added: compliance with the policies or procedures may deteriorate.
+Added: Management assessed the effectiveness of our internal control over financial
+Added: reporting at December 31, 2022.
+Added: In making these assessments, management used the criteria set forth by the Committee of Sponsoring
+Added: Organizations of the Treadway Commission (COSO) in Internal Control — Integrated Framework (2013).
+Added: Based on our assessments and
+Added: those criteria, management determined that our internal controls over financial reporting were effective as of December 31, 2022.
+Added: This Report does not include an attestation report of our independent
+Added: registered public accounting firm due to our status as an emerging growth company and a smaller reporting company.
Changes in Internal Control Over Financial Reporting
2 unchanged sentences
internal control over financial reporting.
−Removed: EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.
−Removed: The information required by Item 10 is incorporated
−Removed: by reference to our Proxy Statement for our 2022 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange
−Removed: Commission no later than 120 days from the end of our 2021 fiscal year.
−Removed: COMPENSATION .
−Removed: The information required by Item 11 is incorporated
−Removed: by reference to our Proxy Statement for our 2022 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange
−Removed: Commission no later than 120 days from the end of our 2021 fiscal year.
−Removed: SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.
−Removed: The information required by Item 12 is incorporated
−Removed: by reference to our Proxy Statement for our 2022 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange
−Removed: Commission no later than 120 days from the end of our 2021 fiscal year.
−Removed: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE.
−Removed: The information required by Item 13 is incorporated
−Removed: by reference to our Proxy Statement for our 2022 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange
−Removed: Commission no later than 120 days from the end of our 2021 fiscal year.
−Removed: ACCOUNTANT FEES AND SERVICES.
−Removed: The information required by Item 14 is incorporated
−Removed: by reference to our Proxy Statement for our 2022 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange
−Removed: Commission no later than 120 days from the end of our 2021 fiscal year.
−Removed: AND FINANCIAL STATEMENT SCHEDULES .
+Added: OTHER INFORMATION.
+Added: DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT
+Added: DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.
+Added: Executive Officers and Directors
+Added: The following table provides information regarding our key employees
+Added: and directors:
+Added: Executive Officers
+Added: President, Chief Executive Officer and Chairman
+Added: Frances Scally
+Added: Chief Financial Officer and Secretary
+Added: Non-Employee Directors
+Added: Douglas Miscoll
+Added: David Pfeffer
+Added: Executive Officers
+Added: Daniel Jones is our Chief Executive Officer and Chairman
+Added: of the Board.
+Added: He has been our co-founder, President, and a member of our board of directors since our inception.
+Added: He has served as Chief
+Added: Executive Officer since May 2018 and was elected Chairman of the Board in March 2021.
+Added: Prior to becoming our CEO, he was President
+Added: from inception to May 2018.
+Added: Jones has over 15 years of biotechnology industry experience, including 12 plus years
+Added: in single molecule sequencing research.
+Added: Prior to founding our company, Mr.
+Added: Jones held various positions at Helicos Biosciences, a
+Added: publicly-traded biotechnology tools company.
+Added: During his career at Helicos Biosciences, his responsibilities included applications development,
+Added: instrument prototyping and validation, customer support and bioinformatics analysis, as well as sales and operations.
+Added: ran the first ever direct RNA sequencing experiments while at Helicos.
+Added: From December 2003 to March 2007, Mr.
+Added: Genomics in the Methods Development group and on development of its Trilogy 2020 Single Molecule Analyzer and Direct miRNA
+Added: From December 2002 to December 2003, Mr.
+Added: Jones worked at EXACT Sciences on its ColoGuard assay, a non-invasive,
+Added: now FDA-approved molecular diagnostic for colorectal cancer.
+Added: Jones has authored or co-authored four publications and is named
+Added: on multiple patents or patent applications.
+Added: He holds a B.S.
+Added: degree from Trinity College and has studied biotechnology and bioinformatics
+Added: at Brandeis University and the University of Massachusetts.
+Added: We believe Mr.
+Added: Jones’ experience in the pharmaceutical industry
+Added: as well as his extensive understanding of our business, operations and strategy qualifies him to serve on our board of directors.
+Added: Frances Scally has served as our Chief Financial Officer
+Added: and Secretary since August 2022.
+Added: Scally has over 30 years’ experience in strategic accounting and financial leadership,
+Added: including serving as chief financial officer, chief accounting officer and in other senior financial executive roles at both domestic
+Added: and multi-national public and private companies.
+Added: Since October 2021, Ms.
+Added: Scally has been a Managing Director at DLA LLC, an Advisory
+Added: firm, in which capacity she provides accounting advisory services.
+Added: Prior to joining DLA LLC, Ms.
+Added: Scally was the Chief Accounting Officer
+Added: and Acting Chief Financial Officer of Aceto Holdings, L.P.
+Added: from April 2019 to April 2020, as well as the Chief Accounting Officer
+Added: of Aceto Corporation from March 2007 to April 2019.
+Added: Aceto Corporation is an international company engaged in the development,
+Added: marketing, sale and distribution of human health products, pharmaceutical ingredients and performance chemicals.
+Added: Prior to joining Aceto,
+Added: Scally was the Director of Financial Reporting and Compliance at Veeco Instruments Inc., a manufacturer of semiconductor process equipment,
+Added: from 1998-2007.
+Added: From 1989-1998, Ms.
+Added: Scally was employed by Ernst & Young LLP.
+Added: Scally received a bachelor’s
+Added: degree in accounting from LIU Post and is a Certified Public Accountant.
+Added: She is a member of New York State Society of CPAs and American
+Added: Institute of Certified Public Accountants.
+Added: Scally also is a Trustee and a member of the Finance Committee for St.
+Added: Edward the Confessor
+Added: Church and School.
+Added: Scally’s services as our Chief Financial Officer are being
+Added: secured pursuant to the terms of our Master Services Agreement with DLA LLC, where Ms.
+Added: Scally is an employee.
+Added: Non-Employee Directors
+Added: has served as a member of
+Added: our board of directors since August 2021.
+Added: Since September 2020, Dr.
+Added: Milos has been Vice President, Scientific Operations
+Added: of Proof Diagnostics, Inc., a company that is developing a low-cost, rapid diagnostic, point-of-care testing platform for the detection
+Added: From October 2016 to September 2020, Dr.
+Added: Milos was a co-founder, President and Chief Executive Officer of
+Added: Medley-Genomics Inc., a company focused on using advanced data analytics to support better diagnosis and treatment of complex diseases.
+Added: From May 2013 to January 2016, Dr.
+Added: Milos was President and Chief Executive Officer of Claritas Genomics Inc., a subsidiary
+Added: of Boston Children’s Hospital that provided commercial next-generation pediatric molecular diagnostic testing.
+Added: Additional experience
+Added: included executive roles at Helicos BioSciences and Pfizer, Inc.
+Added: Milos is also a member of the board of directors of 54Gene Inc.,
+Added: and Nigeria-based startup that collects African genetic code for use in health research and drug development, Slater
+Added: Technology Fund, a seed-stage venture investor in early-stage technology ventures, ProThera Biologics, a life-sciences company
+Added: developing a fundamentally new paradigm for treating severe inflammation and RI Bio, a bioscience, biotech, health and life sciences industry
+Added: network group dedicated to galvanizing collaboration among industry participants.
+Added: Milos has received numerous awards and honors
+Added: within the life sciences industry and has authored or co-authored over 60 biotech or life sciences publications.
+Added: She earned a B.A.
+Added: in biology and chemistry from The College of Saint Rose, a M.S.
+Added: in plant molecular genetics and biology from Rensselaer Polytechnic
+Added: Institute and has completed Post-Doctoral work at Harvard University and Brown University in plant and mouse molecular genetics.
+Added: We believe Dr.
+Added: Milos’ management experience and her extensive
+Added: background and experience in molecular genetics and biology qualifies her to serve on our board of directors.
+Added: Douglas Miscoll has served as a member of our board of
+Added: directors since October 2015.
+Added: Miscoll founded Ravello Precision Partners in 2015, which operated as a hedge fund focused
+Added: on genomic biology companies.
+Added: Miscoll founded Ravello Partners LLC in 2010, which manages discretionary portfolios for families
+Added: and small institutions and is active in the biotechnology sector.
+Added: From 1999 until 2009, Mr.
+Added: Miscoll was a Managing Director at Newlight
+Added: Management, where he was responsible for managing all aspects of two private equity funds and a hedgefund focused on technology, media
+Added: and communications companies.
+Added: He originated and directed the firm’s public market investment activities.
+Added: Previously, from 1994 to
+Added: 1995, he was a Managing Director of Northgate Ventures, a venture capital fund focused on early stage technology companies.
+Added: was a founding member of the management team that created K-III Communications, a leveraged build-up in the publishing and information
+Added: services industries sponsored by Kohlberg Kravis Roberts & Co.
+Added: Miscoll received an M.B.A.
+Added: from Georgetown University,
+Added: a Graduate Certificate from Templeton College, Oxford University, and a B.A.
+Added: from Santa Clara University.
+Added: We believe Mr.
+Added: Miscoll’s executive management experience
+Added: qualifies him to serve on our board of directors.
+Added: David Pfeffer has served as a member of our board of
+Added: directors since September 2018 and is currently our Audit Committee Chairman.
+Added: Pfeffer has over 30 years of experience
+Added: in diverse roles in financial services;
+Added: leading companies, developing and executing strategy, building businesses up from the ground floor
+Added: and driving innovation to grow in today’s ultra-competitive and dynamic global economy.
+Added: Pfeffer is currently CEO of
+Added: Brick Citi Capital, LLC, an investment services and business advisory firm founded in 2019.
+Added: Previously, he was Executive Vice President
+Added: and Chief Financial Officer of Oppenheimer Funds, a global asset manager, from 2004 to 2019.
+Added: He was a Management Director on the Oppenheimer
+Added: board and President of Oppenheimer Funds Harbourview Asset Management.
+Added: From 2009 to 2019, Mr.
+Added: Pfeffer served as an Independent
+Added: Director at ICI Mutual Insurance Co., including a role as Audit Committee Chairman.
+Added: From 2000 to 2004, Mr.
+Added: Pfeffer worked as Institutional
+Added: Chief Financial Officer and Director at Citigroup Asset Management.
+Added: Pfeffer was at J.P.
+Added: Morgan from 1984 to 2000, where
+Added: he gained significant international experience serving as Chief Financial Officer and Director of JPM Brazil for five years in São
+Added: Paulo and supported JPM’s international businesses during his 16 year tenure there.
+Added: Pfeffer worked as a public accountant
+Added: at Ernst & Whinney from 1981 to 1984.
+Added: Pfeffer is a Certified Public Accountant, a Chartered Global Management Accountant
+Added: and has his FINRA Series 99 Operations Professional license.
+Added: He graduated Cum Laude from the University of Delaware with a B.S.
+Added: We believe Mr.
+Added: Pfeffer’s experience in corporate governance
+Added: and capital markets qualifies him to serve on our board of directors.
+Added: Family Relationships
+Added: There are no family relationships between or among any of our directors
+Added: or executive officers.
+Added: There are no family relationships among our officers and directors and those of our subsidiaries and affiliated
+Added: Board Composition and Classified Board Structure
+Added: In accordance with the terms of our restated certificate of incorporation
+Added: and amended and restated bylaws, our Board is currently divided into three classes with staggered, three-year terms.
+Added: At each annual
+Added: meeting of stockholders, the successor to each director whose term then expires will be elected to serve from the time of election and
+Added: qualification until the third annual meeting of stockholders following election or such director’s death, resignation or removal,
+Added: whichever is earliest to occur.
+Added: The current class structure is as follows:
+Added: Class I (consisting of Mr.
+Added: Jones and Dr.
+Added: whose term currently expires at the 2025 Annual Meeting of Stockholders;
+Added: Class II (consisting of Mr.
+Added: Miscoll), whose term will
+Added: expire at the 2023 Annual Meeting of Stockholders;
+Added: and Class III (consisting of Mr.
+Added: Pfeffer), whose term will expire at the
+Added: 2024 Annual Meeting of Stockholders.
+Added: The primary responsibilities of our board of directors are to provide
+Added: oversight, strategic guidance, counseling and direction to our management.
+Added: Our board of directors meets on a regular basis.
+Added: Upon completion
+Added: of this offering, our bylaws will be amended and restated to provide that the authorized number of directors may be changed only by resolution
+Added: of the board of directors.
+Added: We have no formal policy regarding board diversity.
+Added: Our priority in selection of board members is identification
+Added: of members who will further the interests of our stockholders through his or her established record of professional accomplishment, the
+Added: ability to contribute positively to the collaborative culture among board members, knowledge of our business and understanding of the
+Added: competitive landscape.
+Added: Director Independence
+Added: The Nasdaq Marketplace Rules require a majority of a listed company’s
+Added: board of directors to be comprised of independent directors within one year of listing.
+Added: In addition, the Nasdaq Marketplace Rules require
+Added: that, subject to specified exceptions, each member of a listed company’s audit, compensation and nominating and corporate governance
+Added: committees be independent and that audit committee members also satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act.
+Added: Under Rule 5605(a)(2) of the Nasdaq Marketplace Rules, a
+Added: director will only qualify as an “independent director” if, in the opinion of our board of directors, that person does not
+Added: have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.
+Added: In order to be considered independent for purposes of Rule 10A-3 of the Exchange Act, a member of an audit committee of a listed
+Added: company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee,
+Added: accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries
+Added: or otherwise be an affiliated person of the listed company or any of its subsidiaries.
+Added: Our board of directors has reviewed the composition of our board of
+Added: directors and its committees and the independence of each director.
+Added: Based upon information requested from and provided by each director
+Added: concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that
+Added: each of Patrice Milos, Doug Miscoll and David Pfeffer is an “independent director” as defined under Rule 5605(a)(2) of
+Added: the Nasdaq Marketplace Rules.
+Added: Our board of directors also determined that the directors who serve on our audit committee, our compensation
+Added: committee and our nominating and corporate governance committee satisfy the independence standards for such committees established by
+Added: the SEC and the Nasdaq Marketplace Rules, as applicable.
+Added: In making such determinations, our board of directors considered the relationships
+Added: that each such non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant
+Added: in determining independence, including the beneficial ownership of our capital stock by each non-employee director.
+Added: Board Diversity
+Added: In August 2021, the SEC approved a Nasdaq Stock Market proposal to
+Added: adopt new listing rules relating to board diversity and disclosure.
+Added: As approved by the SEC, the new Nasdaq listing rules require all Nasdaq
+Added: listed companies to disclose consistent, transparent diversity statistics regarding their boards of directors.
+Added: The Board Diversity Matrix
+Added: below presents the Board’s diversity statistics in the format prescribed by the Nasdaq rules.
+Added: Board Diversity Matrix (As of March 7, 2023)
+Added: Total Number of Directors
+Added: Gender Identity
+Added: Demographic Background
+Added: African American or Black
+Added: Alaskan Native or Native American
+Added: Hispanic or Latin
+Added: Native Hawaiian or Pacific Islander
+Added: Two or More Races or Ethnicities
+Added: Did Not Disclose Demographic Background
+Added: Board Meetings and Committees
+Added: During the year ended December 31, 2022,
+Added: our board of directors held ten meetings (including regularly scheduled and special meetings), and no director attended fewer than 75%
+Added: of the total number of meetings of the board of directors and the committees of which he or she was a member.
+Added: In addition, during the
+Added: year ended December 31, 2022, our board of directors acted by unanimous written consent on two occasions.
+Added: Although we do not have a formal policy regarding attendance by members
+Added: of our board of directors at annual meetings of stockholders, we encourage, but do not require, directors to attend.
+Added: Our board of directors has established three standing committees — audit,
+Added: compensation, and nominating and corporate governance — each of which operates under a charter approved by our board
+Added: of directors.
+Added: Copies of each committee’s charter has been posted on the Investor Relations section of our website, which is located
+Added: at www.seqll.com .
+Added: Each committee has the composition and responsibilities described below.
+Added: Our board of directors may from time
+Added: to time establish other committees.
+Added: Audit Committee
+Added: Our audit committee consists of David Pfeffer, who is the chair of
+Added: the committee, Douglas Miscoll and Patrice Milos.
+Added: Our board of directors has determined that each of the members of our audit committee
+Added: satisfies the Nasdaq Marketplace Rules and SEC independence requirements.
+Added: The functions of this committee include, among other things:
+Added: the performance, independence and qualifications of our independent auditors and determining whether to retain our existing independent
+Added: auditors or engage new independent auditors;
+Added: and approving the engagement of our independent auditors to perform audit services and any permissible non-audit services;
+Added: our annual and quarterly financial statements and reports, including the disclosures contained under the caption “Management’s
+Added: Discussion and Analysis of Financial Condition and Results of Operations,” and discussing the statements and reports with our independent
+Added: auditors and management;
+Added: with our independent auditors and management significant issues that arise regarding accounting principles and financial statement presentation
+Added: and matters concerning the scope, adequacy and effectiveness of our financial controls;
+Added: our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management
+Added: is implemented;
+Added: and evaluating on an annual basis the performance of the audit committee, including compliance of the audit committee with its charter.
+Added: Our board of directors has determined that David Pfeffer qualifies
+Added: as an “audit committee financial expert” within the meaning of applicable SEC regulations and meets the financial sophistication
+Added: requirements of the Nasdaq Marketplace Rules.
+Added: In making this determination, our board of directors has considered Mr.
+Added: extensive financial experience and business background.
+Added: Both our independent registered public accounting firm and management periodically
+Added: meets privately with our audit committee.
+Added: committee had ten meetings in 2022.
+Added: The audit committee operates
+Added: under a written charter that was adopted by our board of directors and satisfies the applicable rules of the SEC and the listing standards
+Added: of the NASDAQ Stock Market.
+Added: A copy of the audit committee charter is available on our website at www.seqll.
+Added: Compensation Committee
+Added: Our compensation committee consists of Douglas Miscoll, who is the
+Added: chair of the committee, and David Pfeffer and Patrice Milos.
+Added: Our Board has determined that each of the members of our compensation committee
+Added: satisfies the Nasdaq Marketplace Rules independence requirements.
+Added: The functions of this committee include, among other things:
+Added: modifying and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) our overall compensation
+Added: strategy and policies;
+Added: and approving the compensation, the performance goals and objectives relevant to the compensation, and other terms of employment of our
+Added: executive officers;
+Added: and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) the equity incentive plans,
+Added: compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs;
+Added: and approving the terms of any employment agreements, severance arrangements, change in control protections and any other compensatory
+Added: arrangements for our executive officers;
+Added: with management and approving our disclosures under the caption “Compensation Discussion and Analysis” in our periodic reports
+Added: or proxy statements to be filed with the SEC;
+Added: the report that the SEC requires in our annual proxy statement.
+Added: None of our executive officers currently serves, or in the past fiscal
+Added: year has served, as a member of the board of directors or compensation committee of another entity that had one or more of its executive
+Added: officers serving as a member of our board of directors or compensation committee.
+Added: None of the members of our compensation committee has
+Added: been at any time one of our officers or employees.
+Added: Our compensation
+Added: committee had two meetings in 2022.
+Added: The compensation committee
+Added: operates under a written charter that was adopted by our board of directors and satisfies the applicable rules of the SEC and the listing
+Added: standards of the NASDAQ Stock Market.
+Added: A copy of the compensation committee charter is available on our website at www.seqll.com .
+Added: Nominating and Corporate Governance Committee
+Added: Our nominating and corporate governance committee consists of Douglas
+Added: Miscoll, who is the chair of the committee, and Patrice Milos and David Pfeffer.
+Added: Our board of directors has determined that each of the
+Added: members of this committee satisfies the Nasdaq Marketplace Rules independence requirements.
+Added: The functions of this committee include, among
+Added: other things:
+Added: ● identifying,
+Added: reviewing and evaluating candidates to serve on our board of directors consistent with criteria approved by our board of directors;
+Added: director performance on our board of directors and applicable committees of our board of directors and determining whether continued
+Added: service on our board of directors is appropriate;
+Added: ● evaluating,
+Added: nominating and recommending individuals for membership on our board of directors;
+Added: nominations by stockholders of candidates for election to our board of directors.
+Added: our nominating and corporate governance committee met one time .
+Added: The nominating and corporate governance committee operates under a written charter that was adopted by our board of directors and satisfies
+Added: the applicable rules of the SEC and the listing standards of the NASDAQ Stock Market.
+Added: A copy of the nominating and corporate governance
+Added: committee charter is available on our website at www.seqll.com .
+Added: Scientific Advisors
+Added: Our executive team is supported by our Scientific Advisors.
+Added: The Scientific
+Added: Advisors provide scientific advice regarding our tSMS technology to our executive team.
+Added: Each our Scientific Advisors was selected based
+Added: on experience with our tSMS technology and familiarity with our tSMS sequencers.
+Added: The Scientific Advisors are not required to provide any
+Added: particular services to us and are not currently compensated, except for periodic awards of stock options.
+Added: Efrat Shema, Ph.D.
+Added: — Principal Investigator
+Added: and Assistant Professor at the Weizmann Institute of Science.
+Added: Shema completed her M.Sc.
+Added: at the Weizmann Institute in
+Added: 2007 and 2012 in molecular cell biology, after earning her B.Sc.
+Added: in life sciences at the Hebrew University in Jerusalem in 2005.
+Added: to Boston in 2012 as a Fulbright Scholar, conducting post-doctoral work under Dr.
+Added: Bradley Bernstein at Massachusetts General Hospital,
+Added: Harvard Medical School, and the Broad Institute of MIT and Harvard.
+Added: During her Ph.D.
+Added: studies at the Weizmann Institute, Dr.
+Added: received a prestigious Adams Fellowship from the Israel Academy of Sciences and Humanities, as well as the Otto Schwartz Prize for Excellence
+Added: and a UNESCO-L’OREAL national award for young women in life sciences.
+Added: Shema collaborates with us to study epigenetic events
+Added: that contribute to cellular differentiation, early development and cancer using innovative single-molecule technologies.
+Added: Claes Wahlestedt, M.D., Ph.D.
+Added: Center for Therapeutic Innovation, Leonard M.
+Added: Miller Professor and Associate Dean for therapeutic innovation at the University of
+Added: From 2005 to 2011, he was a professor and director of neuroscience at The Scripps Research Institute.
+Added: The author of over 300 papers
+Added: in scientific journals, with over 43,000 citations, Dr.
+Added: Wahlestedt has a long-standing interest in genomics and epigenetics and has
+Added: pioneered various translational efforts in these fields.
+Added: At Scripps in 2008, he co-founded CuRNA (now part of Opko Health), a spin-off
+Added: company based on his patent for targeting regulatory noncoding RNAs to up-regulate therapeutic proteins.
+Added: In 2011, he co-founded Epigenetix
+Added: Inc., a University of Miami spin-off focusing on small molecule drugs for a variety of drug targets in cancer and neuroscience.
+Added: advises us on applications development and scientific strategy.
+Added: Philipp Kapranov, Ph.D.
+Added: — Professor and Director,
+Added: Institute of Genomics at HuaQiao University, Xiamen, China.
+Added: Kapranov’s primary research interest includes systems biology
+Added: and genomics in the context of gene expression and discovery of new RNA species (both protein-coding and non-coding) and their functions,
+Added: especially in the context of human disease particularly cancer.
+Added: Kapranov received his B.Sc.
+Added: in microbial biotechnology, from
+Added: Kiev Institute of Food Industry, Ukraine, and his Ph.D.
+Added: in genetics from Michigan State University.
+Added: Previously, he was a Senior Scientist
+Added: at Affymetrix where his research first demonstrated an order of magnitude increase in transcriptional activity on human chromosomes 21
+Added: and 22 over that accounted for by previously characterized and predicted exons.
+Added: Kapranov is a long-time collaborator of ours
+Added: who purchased and deployed the first HeliScope in China, which his lab uses for researching non-coding RNA and basic science.
+Added: Code of Business Conduct and Ethics
+Added: Our board of directors has adopted a written code of conduct that applies
+Added: to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting
+Added: officer or controller, or persons performing similar functions.
+Added: A current copy of the code and all disclosures that are required by law
+Added: or Nasdaq Marketplace Rules concerning any amendments to, or waivers from, any provision of the code is posted on our website, which is
+Added: located at www.seqll.com .
+Added: Board Leadership Structure
+Added: Our board of directors is free to select the Chairman of the board
+Added: of directors and a Chief Executive Officer in a manner that it considers to be in the best interests of our company at the time of selection.
+Added: Currently, Daniel Jones serves as our Chief Executive Officer and Chairman of the board of directors.
+Added: We currently believe that this leadership
+Added: structure is in our best interests.
+Added: As Chairman of the Board, Mr.
+Added: Jones’ key responsibilities include facilitating communication
+Added: between our board of directors and management, assessing management’s performance, managing board members, preparation of the agenda
+Added: for each board meeting, acting as chair of board meetings and meetings of our company’s stockholders and managing relations with
+Added: stockholders, other stakeholders and the public.
+Added: We will take steps to ensure that adequate structures and processes
+Added: are in place to permit our board of directors to function independently of management.
+Added: The directors will be able to request at any time
+Added: a meeting restricted to independent directors for the purposes of discussing matters independently of management and are encouraged to
+Added: do so should they feel that such a meeting is required.
+Added: Our board of directors, as a whole and also at the committee level,
+Added: plays an active role overseeing the overall management of our risks.
+Added: Our Audit Committee reviews risks related to financial and operational
+Added: items with our management and our independent registered public accounting firm.
+Added: Our board of directors is in regular contact with our
+Added: Chief Executive Officer and Chief Financial Officer, who report directly to our board of directors and who supervise day-to-day risk
+Added: Role of Board in Risk Oversight Process
+Added: We face a number of risks, including those described herein under
+Added: the caption “Risk Factors.” Our board of directors believes that risk management is an important part of establishing, updating
+Added: and executing on our business strategy.
+Added: Our board of directors has oversight responsibility relating to risks that could affect our corporate
+Added: strategy, business objectives, compliance, operations, and the financial condition and performance.
+Added: Our board of directors focuses its
+Added: oversight on the most significant risks facing us and, on our processes, to identify, prioritize, assess, manage and mitigate those risks.
+Added: Our board of directors receives regular reports from members of our senior management on areas of material risk to us, including strategic,
+Added: operational, financial, legal and regulatory risks.
+Added: While our board of directors has an oversight role, management is principally tasked
+Added: with direct responsibility for management and assessment of risks and the implementation of processes and controls to mitigate their
+Added: effects on us.
+Added: EXECUTIVE COMPENSATION .
+Added: The following table sets forth total compensation paid to our named
+Added: executive officers for the years ended December 31, 2022 and 2021 .
+Added: Individuals we refer to as our “named executive officers”
+Added: include our Chief Executive Officers and our Chief Financial Officer whose salary and bonus for services rendered in all capacities exceeded
+Added: $100,000 during the fiscal year ended December 31, 2022.
+Added: Currently, we do not have employment agreements with any of our executive
+Added: officers, although we may enter into employment agreements with our officers in the future.
+Added: Name and Principal Position
+Added: Option Awards (1)
+Added: Non-Equity Incentive Plan Compensation
+Added: Nonqualified Deferred Compensation Earnings
+Added: All Other Compensation
+Added: Chief Executive Officer
+Added: Chief Financial Officer
+Added: Frances Scally (5)
+Added: amounts reported in the “Option Awards” column reflect the aggregate fair value of stock-based compensation awarded during
+Added: the year computed in accordance with the provisions of the Financial Accounting Standard Board Accounting Standards Codification
+Added: Topic 718, or ASC 718.
+Added: See Note 2 to our consolidated financial statements for the year ended December 31, 2022
+Added: included in this report regarding assumptions underlying the valuation of equity awards.
+Added: These amounts reflect the accounting cost for
+Added: these stock options and do not reflect the actual economic value that may be realized by the named executive officer upon the vesting
+Added: of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options.
+Added: this bonus, $75,000 was deferred to, and paid in, 2022.
+Added: resigned his position as our Chief Financial Officer on August 9, 2022.
+Added: $50,000 bonus was paid in 2023.
+Added: Scally was appointed our Chief Financial Officer on August 8, 2022.
+Added: Scally is a consultant to our company and all compensation for
+Added: her services is paid to DLA, LLC, a financial consulting firm with which Ms.
+Added: Scally is employed.
+Added: Equity Compensation Plan Information
+Added: The following table provides information as of December 31,
+Added: 2022, regarding our compensation plans under which equity securities are authorized for issuance:
+Added: Plan category
+Added: Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights
+Added: Weighted- Average Exercise Price of Outstanding Options, Warrants and Rights
+Added: Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column
+Added: 2014 Equity Incentive Plan – Equity compensation plan approved by security holders
+Added: Equity compensation plans not approved
+Added: by security holders
+Added: 2014 Equity Incentive Plan
+Added: Our board of directors and our stockholders originally approved our
+Added: 2014 Equity Incentive Plan, or the 2014 Plan, in April 2014.
+Added: Our 2014 Plan allows for the grant of equity-based awards to our and
+Added: our affiliates’ officers, employees, directors and key persons.
+Added: On March 18, 2021, our board of directors and stockholders
+Added: approved an amendment and restatement of our 2014 Plan to increase the number of shares of common stock available for equity awards under
+Added: the 2014 plan to 3.5 million shares.
+Added: The description below is of our 2014 Plan as amended and restated, except as otherwise noted.
+Added: The purpose of our 2014 Plan, as amended and
+Added: restated, is to encourage and enable our and our affiliates’ officers, employees, directors and other key persons (including consultants
+Added: and prospective employees) upon whose judgment, initiative and efforts we largely depend for the successful conduct of our business to
+Added: acquire a proprietary interest in our company.
+Added: Participants in our 2014 Plan may include
+Added: full or part-time officers, employees, directors and key persons (including advisors and consultants) of our company or our affiliates
+Added: who are selected to receive awards from time to time by the administrator in its sole discretion.
+Added: Administration.
+Added: Our 2014 Plan is administered by our
+Added: compensation committee, or, if at any time our compensation committee is not in existence, our board of directors.
+Added: In addition, to the
+Added: extent applicable law permits, our board of directors may delegate any of its authority under our 2014 Plan to another committee or one
+Added: or more officers, and our compensation committee may delegate any of its authority hereunder to a sub-committee or to one or more officers,
+Added: except that no such delegation is permitted with respect to awards made to individuals who are subject to Section 16 of the Exchange Act
+Added: unless the delegation is to another committee consisting entirely of “nonemployee directors” within the meaning of Rule 16b-3
+Added: of the Exchange Act.
+Added: Subject to the provisions of our 2014 Plan, the administrator has the power to administer the plan, including
+Added: but not limited to, the power to select the eligible officers, employees, directors, and key employees to whom awards are granted;
+Added: determine the number of shares to be covered by each award;
+Added: to determine the terms and conditions of any award and to amend any outstanding
+Added: Authorized Shares.
+Added: As of December 31, 2022, a total of
+Added: 3,500,000 shares of our common stock were authorized for issuance under our 2014 Plan, and at such date, stock grants of an aggregate
+Added: of 2,003,919 shares had been made under the 2014 Plan, and 1,496,081 shares authorized under the 2014 Plan remained available
+Added: for award purposes.
+Added: All of the authorized shares may be issued pursuant to incentive stock options.
+Added: The shares available for issuance
+Added: may be authorized but unissued shares or shares reacquired by us and held in its treasury.
+Added: The share reserve under our 2014 Plan is depleted
+Added: by the maximum number of shares, if any, that may be issuable under an award as determined at the time of grant.
+Added: However, awards that
+Added: may only be settled in cash (determined at the time of grant) do not deplete the share reserve.
+Added: If (1) an award lapses, expires, terminates or is cancelled without
+Added: the issuance of shares, (2) it is determined during or at the conclusion of the term of an award that all or some portion of the
+Added: shares with respect to which the award was granted will not be issuable on the basis that the conditions for such issuance will not be
+Added: satisfied, (3) shares are forfeited under an award, (4) shares are issued under any award and we subsequently reacquire them
+Added: pursuant to rights reserved upon the issuance, (5) an award or a portion thereof is settled in cash, or shares are withheld by us
+Added: in payment of the exercise price or withholding taxes of an award, then such shares will be recredited to the reserve and may again be
+Added: used for new awards.
+Added: However, shares recredited to reserve pursuant to clause (4) in the preceding sentence may not be issued pursuant
+Added: to incentive stock options.
+Added: Adjustments to Shares.
+Added: If, as a result of any reorganization,
+Added: recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in our capital stock, the
+Added: outstanding shares are increased or decreased or are exchanged for a different number or kind of shares or other securities of our company,
+Added: or additional shares or new or different shares or other securities of our company or other non-cash assets are distributed with respect
+Added: to such shares or other securities, or, if, as a result of any merger, consolidation or sale of all or substantially all of our assets,
+Added: the outstanding shares are converted into or exchanged for a different number or kind of securities of our company or any successor entity
+Added: (or a parent or subsidiary thereof), the administrator will make an appropriate or proportionate adjustment in (1) the maximum number
+Added: of shares reserved for issuance under our 2014 Plan;
+Added: (2) the number and kind of shares or other securities subject to any then outstanding
+Added: awards under our 2014 Plan;
+Added: and (3) the exercise price for each share subject to any then outstanding stock options.
+Added: The administrator
+Added: also may adjust the number of shares subject to outstanding awards and the exercise price and the terms of outstanding awards to take
+Added: into consideration material changes in accounting practices or principles, extraordinary dividends, acquisitions or dispositions of stock
+Added: or property or any other event if it is determined by the administrator that such adjustment is appropriate to avoid distortion in the
+Added: operation of our 2014 Plan, subject to the limitations described in our 2014 Plan.
+Added: Effect of a Sale Event.
+Added: Unless otherwise provided in an award
+Added: or other agreement, upon a “sale event,” if the successor or surviving corporation (or parent thereof) so agrees, then, without
+Added: the consent of any holder of an award (or other person with rights in an award), some or all outstanding awards may be assumed, or replaced
+Added: with the same type of award with similar terms and conditions, subject to adjustments described in our 2014 Plan, by the successor or
+Added: surviving corporation (or parent thereof) in the sale event.
+Added: A “sale event” is generally defined for this purpose as (1) any
+Added: person becoming the beneficial owner of 50% or more of the combined voting power of our then-outstanding securities (subject to exceptions
+Added: and other limitations scribed in our 2014 Plan), (2) our stockholders approving a plan of complete liquidation or dissolution of
+Added: our company, (3) the consummation of (a) an agreement for the sale or disposition of all or substantially all of our assets
+Added: (other than to certain excluded persons), (b) a merger, consolidation or reorganization of our company with or involving any other
+Added: corporation (subject to specified exceptions), or (4) a change in the majority of our board of directors that is not approved by
+Added: a supermajority of the existing board.
+Added: More detailed descriptions and additional information on limitations relating to each of these
+Added: sale events are in our 2014 Plan.
+Added: If, after a sale event in which the awards are assumed or replaced,
+Added: the award holder experiences a termination event as a result of a termination of service without cause, due to death or disability, or
+Added: as a result of a resignation for good reason, in each case within 24 months after a sale event, then the award holder’s awards
+Added: will be vested in full or deemed earned in full (assuming target performance, if applicable).
+Added: To the extent the awards are not assumed or replaced in the sale event,
+Added: then, (1) each option will become immediately and fully vested and, unless the administrator determines otherwise, will be canceled
+Added: on the sale event in exchange for a cash payment equal to the excess of the price paid in the sale event over the exercise price of the
+Added: option, and all options with an exercise price lower than the price paid in the sale event will be canceled for no consideration, (2) restricted
+Added: stock and restricted stock units (not subject to performance goals) will be vested in full and settled, along with any accompanying
+Added: dividend equivalent units, and (3) all awards subject to performance goals with outstanding performance periods will be canceled
+Added: in exchange for a cash payment equal to the amount that would have been due under the award if performance had been satisfied at the better
+Added: of target or the performance trend through the sale event.
+Added: Solely with respect to awards granted on and after the completion of
+Added: this offering, and except as otherwise expressly provided in any agreement with an award holder, if the receipt of any payment by an award
+Added: holder under the circumstances described above would result in the payment by the award holder of any excise tax provided for in Section 280G
+Added: and Section 4999 of the Code, then the amount of such payment shall be reduced to the extent required to prevent the imposition of
+Added: such excise tax.
+Added: Limit on Director Awards.
+Added: The maximum value of awards
+Added: granted during a single fiscal year to any non-employee director, taken together with any cash fees paid during the fiscal year to the
+Added: non-employee director in respect of the director’s service as a member of our board of directors during such year (including service
+Added: as a member or chair of any committees of the board), shall not exceed $800,000 in total value for the first year of service and $400,000
+Added: for future years of service (calculating the value of any such awards based on the grant date fair value of such awards for financial
+Added: reporting purposes).
+Added: Types of Awards.
+Added: Awards under our 2014 Plan may consist
+Added: of incentive stock options, non-qualified stock options, restricted stock awards, unrestricted stock awards, restricted stock units,
+Added: or any combination of those awards.
+Added: Some provisions of our 2014 Plan relating to these award types are summarized below.
+Added: Stock Options.
+Added: A stock option is an award entitling the
+Added: recipient to acquire shares, at such exercise price as determined by the administrator (which may not be lower than the fair market value
+Added: of the underlying shares on the date of grant) and subject to such restrictions and conditions as the administrator may determine at the
+Added: time of grant.
+Added: Conditions may be based on continuing employment (or other service relationship) and/or achievement of pre-established
+Added: performance goals and objectives.
+Added: Stock options granted under our 2014 Plan may be either non-qualified stock options or incentive stock
+Added: Incentive stock options may be granted only to our employees or employees of our subsidiaries, and must certain requirements
+Added: specified in our 2014 Plan and the Code.
+Added: Stock options will become exercisable at such time or times as determined by the administrator
+Added: at or after the grant date and set forth in the stock option agreement.
+Added: The administrator may at any time accelerate the exercisability
+Added: of all or any portion of any stock option.
+Added: Restricted Stock.
+Added: A restricted stock award is a grant
+Added: (or sale, at such purchase price as determined by the administrator) of shares that are subject to such restrictions and conditions as
+Added: the administrator may determine at the time of grant.
+Added: Conditions may be based on continuing employment (or other service relationship)
+Added: or achievement of pre-established performance goals and objectives.
+Added: The terms and conditions of each such agreement shall be determined
+Added: by the administrator.
+Added: Unrestricted Stock.
+Added: The administrator may grant (or sell
+Added: at par value or such higher purchase price determined by the administrator) unrestricted shares, in respect of past services, in exchange
+Added: for cancellation of a compensation right, as a bonus, or any other valid consideration, or in lieu of any cash compensation due to such
+Added: Restricted Stock Units and Dividend Equivalent Units.
+Added: administrator may grant restricted stock units representing the right to receive a future payment of cash, the amount of which is
+Added: determined by reference to our shares, shares or a combination of cash and shares.
+Added: The administrator will determine all terms and conditions
+Added: of an award of restricted stock units, including but not limited to the number granted, in what form they will be settled, whether
+Added: performance goals must be achieved for the restricted stock units to be earned, the length of any vesting or performance period and
+Added: the date of payment, and whether the grant will include dividend equivalent units.
+Added: The administrator will determine all terms and
+Added: conditions of an award of dividend equivalent units, including whether payment will be made in cash or shares.
+Added: However, no dividend
+Added: equivalent units may be paid with respect to restricted stock units that are not earned or that do not become vested.
+Added: Termination of Employment or Service.
+Added: Except as otherwise
+Added: provided in any award agreement or an award holder’s employment offer letter, severance letter or services agreement, or as determined
+Added: by administrator at the time of the award holder’s termination of employment or service:
+Added: the termination is for cause, the award holder will forfeit all outstanding awards immediately upon termination and will not be permitted
+Added: to exercise any stock options following termination.
+Added: the termination is due to the award holder’s death or disability (when the award holder could not have been terminated for cause),
+Added: the award holder will forfeit the unvested portion of any award, and any vested stock options will remain exercisable until the earlier
+Added: of the original stock option expiration date or 12 months from the date of termination.
+Added: the termination was for any reason other than cause, death or disability (when the award holder could not have been terminated for cause),
+Added: the award holder will forfeit the unvested portion of any award, and any vested stock options will remain exercisable until the earlier
+Added: of the original stock option expiration date or three months from the date of termination.
+Added: Term of Plan and Plan Amendments.
+Added: Our 2014 Plan will
+Added: continue until all shares reserved for issuance under our 2014 Plan have been issued, or, if earlier, until such time as the administrator
+Added: terminates our 2014 Plan as described below.
+Added: No incentive stock options may be granted after the ten (10) year anniversary of the
+Added: date of stockholder approval of the amendment and restatement of our 2014 Plan unless the stockholders have approved an extension.
+Added: Our board of directors may, at any time, amend, terminate or discontinue
+Added: our 2014 Plan, except that our stockholders must approve any amendment to the extent approval is required by Section 16 of the Exchange Act,
+Added: the Code, the listing requirements of any principal securities exchange or market on which our shares are then traded or any other applicable
+Added: In addition, stockholders must approve any amendment to our 2014 Plan that would materially increase the number of shares reserved
+Added: (except as permitted by the adjustment provisions of our 2014 Plan) or that would diminish the protections afforded by the anti-repricing
+Added: provisions of our 2014 Plan.
+Added: Any termination of our 2014 Plan will not affect the authority of our
+Added: board of directors and the administrator to administer outstanding awards or affect the rights of award holders with respect to awards
+Added: previously granted to them.
+Added: Award Amendments, Cancellation and Disgorgement.
+Added: to the anti-repricing and other requirements of our 2014 Plan, the administrator may modify, amend or cancel any award.
+Added: However, except
+Added: as otherwise provided in our 2014 Plan or an award agreement, the consent of the award holder is required to any amendment that materially
+Added: diminishes the holder’s rights under the award.
+Added: Our 2014 Plan includes exceptions to the consent requirement for actions necessary
+Added: to comply with applicable law or the listing requirements of securities exchanges, to preserve favorable accounting or tax treatment of
+Added: any award for our company or to the extent the administrator determines that an action does not materially and adversely affect the value
+Added: of the award or is in the best interest of the affected award holder or any other person who has an interest in the award.
+Added: The administrator has full power and authority to terminate or cause
+Added: an award holder to forfeit an award, and require an award holder to disgorge to us, any gains attributable to the award, if the award
+Added: holder engages in any action constituting, as determined by the administrator in its discretion, cause for termination, or a breach of
+Added: any award agreement or any other agreement between the award holder and us or one of our affiliates concerning noncompetition, non-solicitation,
+Added: confidentiality, trade secrets, intellectual property, non-disparagement or similar obligations.
+Added: In addition, any awards granted pursuant
+Added: to our 2014 Plan, and any shares issued or cash paid pursuant to an award, will be subject to any recoupment or claw-back policy that
+Added: is adopted by us from time to time, or any recoupment or similar requirement otherwise made applicable to us by law, regulation or listing
+Added: Repricing and Backdating Prohibited.
+Added: Notwithstanding
+Added: anything in our 2014 Plan to the contrary, and except for the adjustments provided for in our 2014 Plan, neither the administrator nor
+Added: any other person may (1) amend the terms of outstanding stock options to reduce the exercise or grant price of such outstanding stock
+Added: (2) cancel outstanding stock options in exchange for stock options with an exercise or grant price that is less than the
+Added: exercise or grant price of the original stock options;
+Added: or (3) cancel outstanding stock options with an exercise or grant price above
+Added: the current fair market value of a share in exchange for cash or other securities.
+Added: In addition, the administrator may not make a grant
+Added: of a stock option with a grant date that is effective prior to the date the administrator takes action to approve the award.
+Added: The following table sets forth information relating
+Added: to stock option grants made to our named executive officers during the fiscal year ended December 31, 2022.
+Added: January 13, 2022
+Added: January 13, 2022
+Added: (1) Reflects the aggregate fair value computed in accordance with
+Added: the provisions of the Financial Accounting Standard Board Accounting Standards Codification Topic 718, or ASC 718.
+Added: See Note 2 to our consolidated financial statements for the year ended December 31, 2022 included in this report regarding
+Added: assumptions underlying the valuation of equity awards.
+Added: These amounts reflect the accounting cost for these stock options and do not reflect
+Added: the actual economic value that may be realized by the named executive officer upon the vesting of the stock options, the exercise of
+Added: the stock options, or the sale of the common stock underlying such stock options.
+Added: Outstanding Equity Awards at Fiscal Year-End
+Added: The following table sets forth outstanding equity awards to our named
+Added: executive officers as of December 31, 2022.
+Added: Option Awards
+Added: Unexercisable (1)
+Added: Number of Shares or
+Added: Director Compensation
+Added: The following discussion describes the significant
+Added: elements of the expected compensation program for members of our board of directors and its committees.
+Added: The compensation of our directors
+Added: is designed to attract and retain committed and qualified directors and to align their compensation with the long-term interests
+Added: of our shareholders.
+Added: Directors who are also executive officers (each, an “Excluded Director”) will not be entitled to receive
+Added: any compensation for his or her service as a director, committee member or Chair of our board of directors or of any committee of our
+Added: board of directors.
+Added: Director Compensation Arrangements.
+Added: Our non-employee director
+Added: compensation program is designed to attract and retain qualified individuals to serve on our board of directors.
+Added: Our board of directors,
+Added: on the recommendation of our compensation committee, will be responsible for reviewing and approving any changes to the directors’
+Added: compensation arrangements.
+Added: In consideration for serving on our board of directors, each director (other than Excluded Directors) will
+Added: be paid an annual retainer.
+Added: All directors will be reimbursed for their reasonable out-of-pocket expenses incurred while serving as
+Added: Our board of directors has approved the following compensation program
+Added: for the non-employee members of our board of directors.
+Added: Cash Compensation.
+Added: Under such program, we will pay each non-employee director
+Added: a cash fee, payable quarterly, of $4,167 per month for service on our board of directors.
+Added: Equity Awards.
+Added: Each non-employee director will receive
+Added: a one-time initial stock option award for 16,216 shares of our common stock, which options shall vest in arrears in two equal
+Added: tranches on the first and second anniversaries of service on our Board.
+Added: Each non-employee director shall also be eligible to receive
+Added: grants of stock options, each in an amount designated by the Compensation Committee of our board of directors, from any equity compensation
+Added: plan approved by the Compensation Committee of our Board.
+Added: In addition to such compensation, we will reimburse each non-employee director
+Added: for all pre-approved expenses within 30 days of receiving satisfactory written documentation setting out the expense actually
+Added: incurred by such director.
+Added: These include reasonable transportation and lodging costs incurred for attendance at any meeting of our board
+Added: of directors.
+Added: The following table sets forth the director compensation we accrued
+Added: in the year ended December 31, 2022 (excluding compensation to our executive officers set forth in the summary compensation table
+Added: Douglas Miscoll
+Added: David Pfeffer
+Added: Of the amount reported in the “Fees or Paid in Cash” column, $10,000 was deferred to and paid in 2023.
+Added: (2) Reflects the aggregate fair value computed in accordance with
+Added: the provisions of the Financial Accounting Standard Board Accounting Standards Codification Topic 718, or ASC 718.
+Added: See Note 2 to our consolidated financial statements for the year ended December 31, 2022 included in this report regarding
+Added: assumptions underlying the valuation of equity awards.
+Added: These amounts reflect the accounting cost for these stock options and do not reflect
+Added: the actual economic value that may be realized by the named director upon the vesting of the stock options, the exercise of the stock
+Added: options, or the sale of the common stock underlying such stock options.
+Added: SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
+Added: AND RELATED STOCKHOLDER MATTERS.
+Added: The following table sets forth certain information regarding the beneficial
+Added: ownership of our common stock as of March 1, 2023 by:
+Added: person known by us to be a beneficial owner of more than 5% of our outstanding common stock;
+Added: of our directors;
+Added: of our named executive officers;
+Added: directors and executive officers as a group.
+Added: The amounts and percentages of common stock beneficially owned are
+Added: reported on the basis of regulations of the SEC governing the determination of beneficial ownership of securities.
+Added: Under the rules of
+Added: the SEC, a person is deemed to be a “beneficial owner” of a security if that person has or shares “voting power,”
+Added: which includes the power to vote or to direct the voting of such security, or “investment power,” which includes the power
+Added: to dispose of or to direct the disposition of such security.
+Added: A person is also deemed to be a beneficial owner of any securities of which
+Added: that person has a right to acquire beneficial ownership within 60 days after March 1, 2023.
+Added: Under these rules, more than one person
+Added: may be deemed a beneficial owner of the same securities and a person may be deemed a beneficial owner of securities as to which he has
+Added: no economic interest.
+Added: Except as indicated by footnote, to our knowledge, the persons named in the table below have sole voting and investment
+Added: power with respect to all shares of common stock shown as beneficially owned by them.
+Added: The applicable percentage ownership prior to this
+Added: offering is based on 13,886,379 shares of common stock outstanding as of March 1, 2023.
+Added: Unless otherwise noted below, the address of the persons listed on
+Added: the table is c/o SeqLL Inc., 3 Federal Street, Billerica, Massachusetts 01821.
+Added: Name and Address of Beneficial Owner
+Added: Number of Shares
+Added: Executive Officers and Directors
+Added: Daniel Jones (1)
+Added: Frances Scally
+Added: Douglas Miscoll (4)
+Added: David Pfeffer (5)
+Added: All directors and executive officers as a group (6 persons)
+Added: 5% Stockholders
+Added: Laurent Investments, LLC (7)
+Added: beneficial ownership of less than 1%.
+Added: (i) 2,392,365 shares of common stock and (ii) 240,878 shares of common stock issuable upon the exercise of currently exercisable
+Added: stock options.
+Added: (2) Represents
+Added: shares of common stock issuable upon the exercise of currently exercisable stock options.
+Added: (i) 10,000 shares of common stock and (ii) 52,027 shares of common stock issuable upon the exercise of currently exercisable
+Added: stock options.
+Added: (i) 54,729 shares of common stock and (ii) 83,445 shares of common stock issuable upon the exercise of currently exercisable
+Added: stock options.
+Added: (i) 20,000 shares of common stock and (ii) 41,216 shares of common stock issuable upon the exercise of currently exercisable
+Added: stock options.
+Added: (i) 16,216 shares of common stock issuable upon the exercise of currently exercisable stock options and (ii) 744,243 shares
+Added: of common stock held by Mr.
+Added: Laurent’s spouse, (iii) 2,054,403 shares of common stock beneficially owned by St.
+Added: Laurent Investments LLC, (iv) 583,172 shares of common stock beneficially owned by the Georges C.
+Added: Descendants’ Trust and (v) 583,172 shares of common stock beneficially owned by the William C.
+Added: St Laurent Descendant’s
+Added: The address of Mr.
+Added: Laurent is 120 NE 136 Avenue, Vancouver, WA 98684.
+Added: (i) 1,530,583 shares of common stock, and (ii) 523,820 shares of common stock issuable upon the exercise of currently
+Added: exercisable warrants.
+Added: Laurent is the managing member of St.
+Added: Laurent Investments, LLC and, as a result, may be
+Added: deemed to have voting and investment power with respect to the shares held by St.
+Added: Laurent Investments, LLC.
+Added: The address of St.
+Added: Investments, LLC is 120 NE 136 Avenue, Vancouver, WA 98684.
+Added: address of Wendy St.
+Added: Laurent is 120 NE 136 Avenue, Vancouver, WA 98684.
+Added: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR
+Added: INDEPENDENCE.
+Added: Procedures for Approval of Related Party Transactions
+Added: A “related party transaction” is any actual or proposed
+Added: transaction, arrangement or relationship or series of similar transactions, arrangements or relationships, including those involving indebtedness
+Added: not in the ordinary course of business, to which we or our subsidiaries were or are a party, or in which we or our subsidiaries were or
+Added: are a participant, in which the amount involved exceeded or exceeds the lesser of (i) $120,000 or (ii) one percent of the average
+Added: of our total assets at year-end for the last two completed fiscal years and in which any related party had or will have a direct
+Added: or indirect material interest.
+Added: A “related party” includes:
+Added: person who is, or at any time during the applicable period was, one of our executive officers or one of our directors;
+Added: person who beneficially owns more than 5% of our common stock;
+Added: immediate family member of any of the foregoing;
+Added: entity in which any of the foregoing is a partner or principal or in a similar position or in which such person has a 10% or greater
+Added: beneficial ownership interest.
+Added: In March 2021, our board of directors adopted a written related-party transactions
+Added: Pursuant to this policy, the Audit Committee of our board of directors will review all material facts of all related-party transactions
+Added: and either approve or disapprove entry into the related-party transaction, subject to certain limited exceptions.
+Added: In determining
+Added: whether to approve or disapprove entry into a related-party transaction, our Audit Committee shall take into account, among other
+Added: factors, the following:
+Added: (i) whether the related-party transaction is on terms no less favorable to us than terms generally available
+Added: from an unaffiliated third party under the same or similar circumstances;
+Added: (ii) the extent of the related party’s interest in
+Added: the transaction;
+Added: and (iii) whether the transaction would impair the independence of a non-employee director.
+Added: Related Party Transactions
+Added: At December 31, 2022, the Company had the following outstanding payables
+Added: to affiliated parties for past services:
+Added: Genomic Diagnostic Technologies
+Added: Laurent Institute
+Added: Laurent Realty, Inc.
+Added: Total related party payables
+Added: The above entities are affiliated with (1) William C.
+Added: a former member of the Company’s board of directors, (2) relatives of Mr.
+Added: Laurent or (3) entities controlled by the St.
+Added: family, who are controlling shareholders of the Company.
+Added: Laurent Realty, Inc.
+Added: and Genomic Diagnostic Technologies assisted the Company
+Added: by previously providing corporate accounting support;
+Added: Laurent Institute, a non-for-profit company, provided bioinformatics specialist
+Added: support for certain sequencing services.
+Added: From April 29, 2019 to April 29, 2020, we entered into a series of non-convertible
+Added: promissory notes (the “Promissory Notes”) with St.
+Added: Laurent Investments LLC amounting to $1,375,000.
+Added: The Promissory Notes had
+Added: a one-year term with interest accruing at 10% per annum.
+Added: In October 2021, we entered into an agreement with St.
+Added: Laurent Investments LLC
+Added: to reduce the interest on $1,375,000 principal amount of the Promissory Notes from 10% to 5% per year starting on October 1, 2021.
+Added: June 2022, we entered into an agreement with St.
+Added: Laurent Investments LLC to extend the maturity date of the $1,375,000 Promissory Note
+Added: to July 31, 2024.
+Added: PRINCIPAL ACCOUNTANT FEES AND SERVICES.
+Added: The following table sets forth the fees billed to us for professional
+Added: services rendered by Wolf & Co.
+Added: for the years ended December 31, 2022 and 2021:
+Added: Audit-related fees
+Added: Fees — Audit fees consist of fees billed for the audit of our annual financial statements and the review of the interim
+Added: consolidated financial statements.
+Added: (2) Audit-Related
+Added: Fees — These consisted principally of the aggregate fees related to audits that are not included Audit Fees.
+Added: Pre-Approval Policies and Procedures
+Added: The Audit Committee has the authority to appoint or replace our independent
+Added: registered public accounting firm (subject, if applicable, to stockholder ratification).
+Added: The Audit Committee is also responsible for the
+Added: compensation and oversight of the work of the independent registered public accounting firm (including resolution of disagreements between
+Added: management and the independent registered public accounting firm regarding financial reporting) for the purpose of preparing or issuing
+Added: an audit report or related work.
+Added: The independent registered public accounting firm was engaged by, and reports directly to, the Audit
+Added: The Audit Committee pre-approves all audit services and permitted
+Added: non-audit services (including the fees and terms thereof) to be performed for us by our independent registered public accounting firm,
+Added: subject to the de minimis exceptions for non-audit services described in Section 10A(i)(1)(B) of the Exchange Act and
+Added: Rule 2-01(c)(7)(i)(C) of Regulation S-X, provided that all such excepted services are subsequently approved prior to the
+Added: completion of the audit.
+Added: We have complied with the procedures set forth above, and the Audit Committee has otherwise complied with the
+Added: provisions of its charter.
+Added: EXHIBITS AND FINANCIAL STATEMENT SCHEDULES .
Incorporation
−Removed: and Restated Certificate of Incorporation
+Added: Amended and Restated Certificate of Incorporation
Amended and Restated Bylaws
Description of Securities
−Removed: common stock certificate
−Removed: Agency Agreement dated as of August 31, 2021 between SeqLL Inc.
+Added: Specimen common stock certificate
+Added: Warrant Agency Agreement dated as of August 31, 2021 between SeqLL Inc.
and VSTOCK Transfer LLC
−Removed: of Common Stock Purchase Warrant
−Removed: and Restated 2014 Equity Incentive Plan
−Removed: Agreement dated March 15, 2013 between SeqLL, LLC and Helicos Biosciences Corporation
−Removed: Agreement dated March 15, 2013 between SeqLL, LLC and Helicos Biosciences Corporation
−Removed: Rights Agreement dated as of September 30, 2018
+Added: Form of Common Stock Purchase Warrant
+Added: Amended and Restated 2014 Equity Incentive Plan
+Added: License Agreement dated March 15, 2013 between SeqLL, LLC and Helicos Biosciences Corporation
+Added: Sub-License Agreement dated March 15, 2013 between SeqLL, LLC and Helicos Biosciences Corporation
+Added: Investor Rights Agreement dated as of September 30, 2018
Subsidiaries of the Registrant
9 unchanged sentences
Inline XBRL Instance Document.
−Removed: Inline XBRL Taxonomy Extension Schema Document.
−Removed: Inline XBRL Taxonomy Extension Calculation Linkbase Document.
−Removed: Inline XBRL Taxonomy Extension Definition Linkbase Document.
−Removed: Inline XBRL Taxonomy Extension Label Linkbase Document.
−Removed: Inline XBRL Taxonomy Extension Presentation Linkbase Document.
−Removed: Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
+Added: Inline XBRL Taxonomy Extension
+Added: Schema Document.
+Added: Inline XBRL Taxonomy Extension
+Added: Calculation Linkbase Document.
+Added: Inline XBRL Taxonomy Extension
+Added: Definition Linkbase Document.
+Added: Inline XBRL Taxonomy Extension
+Added: Label Linkbase Document.
+Added: Inline XBRL Taxonomy Extension
+Added: Presentation Linkbase Document.
+Added: Cover Page Interactive
+Added: Data File (formatted as Inline XBRL and contained in Exhibit 101).
Filed herewith.
Indicates a management contract or compensatory plan.
−Removed: Pursuant to the requirements
−Removed: of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by
−Removed: the undersigned thereunto duly authorized, on the 23rd day of March, 2022.
+Added: Pursuant to the requirements of Section 13 or 15(d)
+Added: of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
+Added: duly authorized, on the 16th day of March, 2023.
/s/ Daniel Jones
2 unchanged sentences
Exchange Act of 1934, this report has been signed by the following persons in the capacities and on the dates indicated.
−Removed: /s/ Daniel Jones
−Removed: Chief Executive Officer and Chairman
−Removed: March 23, 2022
−Removed: (Principal Executive Officer)
−Removed: Chief Financial Officer and Secretary
−Removed: March 23, 2022
−Removed: (Principal Financial and Accounting Officer)
−Removed: /s/ Douglas Miscoll
−Removed: March 23, 2022
+Added: Executive Officer and Chairman
+Added: Executive Officer)
+Added: Frances Scally
+Added: Financial Officer and Secretary
+Added: Financial and Accounting Officer)
Douglas Miscoll
−Removed: /s/ David Pfeffer
−Removed: March 23, 2022
David Pfeffer
1 unchanged sentence
Patrice Milos
−Removed: March 23, 2022
CONSOLIDATED FINANCIAL STATEMENTS
Index to Consolidated Financial Statements
−Removed: Report of Independent Registered Public Accounting Firm (PCAOB ID# 392 ) F-2
+Added: Report of Independent Registered Public Accounting Firm (PCAOB ID:
Consolidated Balance Sheets F-3
−Removed: Consolidated Statements of Operations F-4
+Added: Consolidated Statements of Operations and Comprehensive Loss F-4
Consolidated Statements of Changes in Stockholders’ Equity (Deficit) F-5
1 unchanged sentence
Notes to the Consolidated Financial Statements F-7
−Removed: OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
−Removed: To the Board of Directors and the Stockholders of SeqLL Inc.:
+Added: REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
+Added: To the Stockholders and the Board of Directors of SeqLL, Inc.:
Opinion on the Financial Statements
−Removed: We have audited the accompanying consolidated balance
−Removed: sheets of SeqLL Inc.
−Removed: (the “Company”) as of December 31, 2021 and 2020, the related consolidated statements of operations,
−Removed: changes in stockholders’ equity (deficit) and cash flows for the years then ended, and the related notes to the consolidated financial
−Removed: statements (collectively referred to as the “financial statements”).
+Added: We have audited the accompanying consolidated balance sheets of SeqLL,
+Added: (the “Company”) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive
+Added: loss, stockholders’ equity (deficit) and cash flows for the years then ended, and the related notes to the consolidated financial
+Added: statements and schedules (collectively, the “financial statements”).
In our opinion, the financial statements present fairly,
−Removed: in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations
−Removed: and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.
+Added: in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and
+Added: its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
−Removed: These financial statements are the responsibility
−Removed: of the Company’s management.
−Removed: Our responsibility is to express an opinion on the Company’s financial statements based on our
−Removed: We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”)
−Removed: and are required to be independent with respect to the Company in accordance with U.S.
−Removed: federal securities laws and the applicable rules
−Removed: and regulations of the Securities and Exchange Commission and the PCAOB.
+Added: These financial statements are the responsibility of the Company’s
+Added: Our responsibility is to express an opinion on the Company’s financial statements based on our audits.
+Added: We are a public
+Added: accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to
+Added: be independent with respect to the Company in accordance with U.S.
+Added: federal securities laws and the applicable rules and regulations of
+Added: the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB.
7 unchanged sentences
Accordingly, we express no such opinion.
−Removed: Our audits included performing procedures to assess
−Removed: the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
−Removed: to those risks.
−Removed: Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
−Removed: Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
−Removed: the overall presentation of the financial statements.
+Added: Our audits included performing procedures to assess the risks of material
+Added: misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.
+Added: Such procedures
+Added: included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
+Added: Our audits also included
+Added: evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
+Added: of the financial statements.
We believe that our audits provide a reasonable basis for our opinion.
1 unchanged sentence
We have served as the Company’s auditor since 2018.
−Removed: Boston, Massachusetts
March 16, 2023
2 unchanged sentences
Cash and cash equivalents
−Removed: Marketable securities, at fair value
−Removed: Accounts receivable, net
+Added: Marketable securities
+Added: Accounts receivable, net of allowance for doubtful accounts of $ 6,016
Other receivables
2 unchanged sentences
Property and equipment, net
−Removed: Liabilities and Stockholders’ Equity (Deficit)
+Added: Operating lease right-of-use asset
+Added: Liabilities and Stockholders’ Equity
Current liabilities
1 unchanged sentence
Accrued expenses
−Removed: Loan payable - related party
−Removed: Non-convertible promissory notes – current portion
+Added: Non-convertible promissory notes - current
+Added: Current portion of operating lease liability
Total current liabilities
Non-current liabilities
−Removed: Convertible notes
−Removed: Non-convertible promissory notes – net of current portion
+Added: Operating lease liability, less current portion
+Added: Non-convertible promissory notes - long-term
Total non-current liabilities
1 unchanged sentence
Commitments and contingencies (Note 14)
−Removed: Stockholders’ equity (deficit)
+Added: Stockholders’ equity
Preferred stock, $ 0.00001 par value;
20,000,000 shares authorized;
−Removed: 0 and 5,791,665 shares issued and outstanding as of December 31, 2021 and 2020, respectively
+Added: 0 shares issued and outstanding
Common stock, $ 0.00001 par value;
80,000,000 shares authorized;
−Removed: 11,886,379 and 4,864,862 shares issued and outstanding as of December 31, 2021 and 2020, respectively
+Added: 11,886,379 shares issued and outstanding
Additional paid-in capital
2 unchanged sentences
( 14,413,851 )
−Removed: Total stockholders’ equity (deficit)
−Removed: ( 3,854,166 )
−Removed: Total liabilities and stockholders’ equity (deficit)
+Added: Accumulated other comprehensive income
+Added: Total stockholders’ equity
+Added: Total liabilities and stockholders’ equity
The accompanying notes are an integral part
of these consolidated financial statements.
−Removed: Consolidated Statements of Operations
+Added: Consolidated Statements of Operations and Comprehensive
Grant revenue
7 unchanged sentences
( 3,997,148 )
+Added: ( 2,548,628 )
Other (income) and expenses
−Removed: Investment income
−Removed: Unrealized loss on marketable securities
+Added: Interest and dividend income
+Added: Unrealized (gain)/loss on marketable equity securities
+Added: Realized loss on marketable equity securities
Change in fair value of convertible notes
3 unchanged sentences
( 3,703,558 )
+Added: Other comprehensive income
+Added: Unrealized gain on marketable debt securities
+Added: Total comprehensive loss
+Added: $ ( 4,072,382 )
+Added: $ ( 3,703,558 )
Net loss per share - basic and diluted
6 unchanged sentences
Preferred Stock
−Removed: Additional Paid-In
−Removed: Total Stockholders’
+Added: Comprehensive
+Added: Stockholders ’
Balance as of December 31, 2020
1 unchanged sentence
$ ( 3,854,166 )
+Added: Conversion of preferred stock into common stock
+Added: ( 5,791,665 )
Stock-based compensation expense
+Added: Conversion of convertible notes into common stock
+Added: Issuance of Units in initial public offering, net of issuance costs of $ 1,555,976
+Added: Issuance of common stock to underwriters in initial public offering, net of issuance costs of $ 71,199
( 3,703,558 )
2 unchanged sentences
$ ( 14,413,851 )
−Removed: $ ( 3,854,166 )
−Removed: Conversion of preferred stock into common stock
−Removed: ( 5,791,665 )
Stock-based compensation expense
−Removed: Conversion of convertible notes into common stock
−Removed: Issuance of Units and warrants in initial public offering, net of issuance costs of $ 1,555,976
−Removed: Issuance of common stock to underwriters in initial public offering, net of issuance costs of $ 71,199
+Added: Other comprehensive income
( 4,094,833 )
9 unchanged sentences
Adjustment to reconcile net loss to net cash used in operating activities:
−Removed: Unrealized loss on marketable securities
+Added: Write-off of obsolete inventory
+Added: Unrealized (gain)/loss on marketable securities
+Added: Realized loss on marketable equity securities
Loss on extinguishment of notes
1 unchanged sentence
Change in fair value of convertible notes
+Added: Non-cash lease expense
Changes in operating assets and liabilities:
4 unchanged sentences
Accrued expenses
−Removed: Deferred revenue
Net cash used in operating activities
( 3,662,568 )
+Added: ( 1,989,877 )
Cash Flows from Investing Activities
Purchases of lab equipment
−Removed: Purchases of marketable securities
+Added: Purchases of marketable equity securities
( 5,976,442 )
−Removed: Net cash used in investing activities
+Added: Purchases of marketable debt securities
( 4,014,153 )
+Added: Sales of marketable equity securities
+Added: Net cash provided by (used in) investing activities
+Added: ( 5,990,912 )
Cash Flows from Financing Activities
2 unchanged sentences
( 1,627,175 )
−Removed: Proceeds from issuance of non-convertible promissory notes
Payment of non-convertible promissory notes
6 unchanged sentences
Net increase (decrease) in cash and cash equivalents
−Removed: Cash and cash equivalents, beginning of year
−Removed: Cash and cash equivalents, end of year
+Added: ( 1,834,603 )
+Added: Cash and cash equivalents, beginning of period
+Added: Cash and cash equivalents, end of period
Supplemental disclosure of cash flow information and non-cash financing transactions
+Added: Right-of-use asset acquired through operating lease
+Added: Leasehold improvements financed through tenant improvement allowance
Conversion of notes at initial public offering into common stock
1 unchanged sentence
Fair value of warrants of common stock issued to underwriters
−Removed: Conversion of 2020 accrued interest into promissory notes
The accompanying notes are an integral part
of these consolidated financial statements.
−Removed: Consolidated Financial Statements
−Removed: December 31, 2021 and 2020
−Removed: Nature of Operations and Basis of Presentation
−Removed: was incorporated as a Delaware corporation
−Removed: on April 3, 2014.
+Added: Notes to Consolidated Financial Statements
+Added: Years Ended December 31, 2022 and 2021
+Added: Note 1 – Nature of Operations
+Added: and Basis of Presentation
+Added: was incorporated as a Delaware corporation on April 3, 2014.
On April 8, 2014, SeqLL Inc.
−Removed: acquired a 100 % ownership interest in SeqLL, LLC (“Subsidiary”), a domestic
−Removed: limited liability company formed on March 11, 2013 in the State of Massachusetts.
−Removed: is a holding company of the Subsidiary (together
−Removed: the “Company” or SeqLL”) and is a life sciences company focused on the development and application of innovative genetic
−Removed: analysis technologies and the monetization of that technology and related intellectual property.
−Removed: The Subsidiary purchased technology to
−Removed: enable the analysis of large volumes of genetic material by directly sequencing single molecules of DNA or RNA.
−Removed: The Subsidiary’s
−Removed: principal office is located in Woburn, Massachusetts.
+Added: acquired a 100 % ownership interest in SeqLL, LLC (“Subsidiary”), a domestic limited liability
+Added: company formed on March 11, 2013 in the State of Massachusetts.
+Added: is a holding company of the Subsidiary (together the “Company”
+Added: or “SeqLL”) and is a life sciences company focused on the development and application of innovative genetic analysis technologies
+Added: and the monetization of these technologies and related intellectual property.
+Added: The Subsidiary owns technology to enable the analysis of
+Added: large volumes of genetic material by directly sequencing single molecules of DNA or RNA.
+Added: The Subsidiary’s principal office is located
+Added: in Billerica, Massachusetts.
Initial Public Offering
−Removed: On August 31, 2021, the Company completed its
−Removed: initial public offering (“IPO”) whereby it sold 3,060,000 units, each unit consisting of one share of the Company’s
−Removed: common stock and a warrant to purchase one share of common stock at an exercise price of $ 4.25 per share (the “Warrants”),
−Removed: at a price to the public of $ 4.25 per unit.
−Removed: The gross proceeds from the IPO were approximately $ 13 million and were offset by $ 3.2 million
−Removed: in offering costs, of which $ 1.6 million was paid in cash and $ 1.6 million was issued in warrants issued to Maxim Group LLC (“Underwriter”)
−Removed: (see Note 10).
−Removed: In connection with the IPO, all of the outstanding shares of the Company’s convertible preferred stock automatically
−Removed: converted into 3,130,622 shares of common stock (see Note 9).
−Removed: Additionally, the outstanding convertible notes converted into 641,895 shares
−Removed: of common stock (see Note 8).
−Removed: Pursuant to the Underwriting Agreement, the Company
−Removed: granted the Underwriter a 45-day option to purchase up to 459,000 additional shares of common stock, and/or 459,000 additional Warrants,
−Removed: to cover over-allotments in connection with the Offering.
−Removed: The Underwriter partially exercised this option and purchased 459,000 Warrants
−Removed: on August 31, 2021, at $ 0.01 per Warrant.
−Removed: On September 29, 2021, the Company issued 189,000 shares of common stock to the underwriters
−Removed: at a price of $ 4.24 per share from the exercise of the overallotment option, raising the net proceeds of approximately $ 730,000 , net of
−Removed: offering costs.
−Removed: On August 31, 2021, and September 29, 2021, the
−Removed: Company also issued to the Underwriter warrants to purchase up to a total of 162,450 shares of common stock at an exercise price of $ 4.675
−Removed: per share (“Underwriter Warrants”) (Note 10).
+Added: On August 31, 2021, the Company completed its initial public offering
+Added: (“IPO”) whereby it sold 3,060,000 units, each unit consisting of one share of the Company’s common stock and a warrant
+Added: to purchase one share of common stock at an exercise price of $ 4.25 per share (the “Warrants”), at a price to the public of
+Added: $ 4.25 per unit.
+Added: The gross proceeds from the IPO were approximately $ 13 million and were offset by $ 3.2 million in offering costs, of which
+Added: $ 1.6 million was paid in cash and $ 1.6 million was issued in warrants to Maxim Group LLC (“Underwriter”) (see Note 10).
+Added: connection with the IPO, all of the outstanding shares of the Company’s convertible preferred stock automatically converted into
+Added: 3,130,622 shares of common stock (see Note 9).
+Added: Additionally, the outstanding convertible notes converted into 641,895 shares of common
+Added: stock (see Note 8).
+Added: Pursuant to the Underwriting Agreement, the Company granted the Underwriter
+Added: a 45-day option to purchase up to 459,000 additional shares of common stock, and/or 459,000 additional Warrants, to cover over-allotments
+Added: in connection with the Offering.
+Added: The Underwriter partially exercised this option and purchased 459,000 Warrants on August 31, 2021, at
+Added: $ 0.01 per Warrant.
+Added: On September 29, 2021, the Company issued 189,000 shares of common stock to the underwriters at a price of $ 4.24 per
+Added: share from the exercise of the overallotment option, raising the net proceeds of approximately $ 730,000 , net of offering costs.
+Added: On August 31, 2021, and September 29, 2021, the Company also issued
+Added: to the Underwriter warrants to purchase up to a total of 162,450 shares of common stock at an exercise price of $ 4.675 per share (“Underwriter
+Added: Warrants”) (Note 10).
+Added: Notice from the Nasdaq Stock Market
+Added: On June 21, 2022, SeqLL received notice from The Nasdaq Stock Market
+Added: (“Nasdaq”) indicating that, because the closing bid price for its common stock has fallen below $ 1.00 per share for 30 consecutive
+Added: business days, the Company no longer complies with the $ 1.00 minimum bid price requirement for continued listing.
+Added: Initially, the Company
+Added: had approximately 180 days to regain its compliance with the Nasdaq.
+Added: On December 20, 2022, the Company filed with, and received notice from,
+Added: the Nasdaq that the Company is eligible for an additional 180 day period, in other words, until June 19, 2023, to regain its Nasdaq compliance.
+Added: The notification of noncompliance has no immediate effect on the listing
+Added: or trading of the Company’s common stock or its warrants to purchase common stock under the symbols “SQL” and “SQLLW,”
+Added: respectively.
+Added: To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for
+Added: a minimum of 10 consecutive business days.
+Added: If the Company does not regain compliance by June 19, 2023, and it
+Added: has been determined that the Company will not be able to cure the deficiency, Nasdaq will provide notice that the Company’s common
+Added: stock will be subject to delisting.
+Added: The Company would have the right to appeal a determination to delist its common stock, and the common
+Added: stock would remain listed on The Nasdaq Capital Market until the completion of the appeal process.
Risks and Uncertainties
−Removed: The Company is subject to a number of risks similar
−Removed: to other companies in its industries, including rapid technological change, competition from larger pharmaceutical and biotechnology companies
−Removed: and dependence on key personnel.
−Removed: The extent of the impact of the COVID-19 pandemic
−Removed: on the Company’s business continues to be highly uncertain and difficult to predict, as the responses that the Company, other businesses
−Removed: and governments are taking continue to evolve.
−Removed: Furthermore, capital markets and economies worldwide have also been negatively impacted
−Removed: by the COVID-19 pandemic, and it is possible that it could cause a lasting national and/or global economic recession.
−Removed: Policymakers around
−Removed: the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole.
−Removed: The magnitude and overall
−Removed: effectiveness of these actions remain uncertain.
−Removed: The severity of the impact of the COVID-19 pandemic on the Company’s
−Removed: business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and
−Removed: severity of the impact on the Company’s service providers, suppliers, contract research organizations and the Company’s clinical
−Removed: trials, all of which are uncertain and cannot be predicted.
−Removed: During 2021 and 2020, the COVID-19 pandemic has adversely affected the Company’s
−Removed: sales and results of operations and may continue to adversely affect its business.
−Removed: The extent to which the COVID-19 pandemic may in the
−Removed: future materially impact the Company’s financial condition, liquidity or results of operations is uncertain.
+Added: The Company is subject to a number of risks similar to other companies
+Added: in its industries, including rapid technological change, competition from larger pharmaceutical and biotechnology companies and dependence
+Added: on key personnel.
+Added: Results of operations may be adversely affected by various factors
+Added: that could cause economic uncertainty and volatility in the financial markets, many of which are beyond the Company’s control.
+Added: Company’s business could be impacted by, among other things, downturns in the financial markets or in economic conditions, inflation,
+Added: increases in interest rates, the ongoing effects of the COVID-19 pandemic, including resurgences and the emergence of new variants, and
+Added: geopolitical instability, such as the military conflict in the Ukraine.
+Added: The Company cannot at this time fully predict the likelihood of
+Added: one or more of the above events, their duration or magnitude or the extent to which they may negatively impact the Company’s business.
Basis of Presentation
−Removed: The accompanying consolidated financial statements
−Removed: include the accounts of SeqLL Inc.
+Added: The accompanying consolidated financial statements include the accounts
+Added: of SeqLL Inc.
and its wholly-owned subsidiary, SeqLL, LLC.
−Removed: All intercompany accounts and transactions have been eliminated
−Removed: in consolidation.
+Added: All intercompany accounts and transactions have been eliminated in consolidation.
Note 2 – Significant Accounting Policies
−Removed: A summary of significant accounting policies followed
−Removed: by the Company in the preparation of the accompanying consolidated financial statements are as follows:
+Added: A summary of significant accounting policies followed by the Company
+Added: in the preparation of the accompanying consolidated financial statements are as follows:
Use of Estimates
5 unchanged sentences
Significant estimates include but are not limited to stock-based compensation
−Removed: expense, research and development accruals, fair value of warrants and loss on extinguishment of notes.
−Removed: Actual results could differ from
−Removed: those estimates and changes in estimates may occur.
+Added: expense, fair value of warrants and loss on extinguishment of notes.
+Added: Actual results could differ from those estimates and changes in estimates
Cash and Cash Equivalents
−Removed: The Company considers all highly liquid securities readily
−Removed: convertible to cash that mature within three months or less from the original date of purchase to be cash equivalents.
−Removed: instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents.
−Removed: Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits.
−Removed: At times, the
−Removed: Company’s cash and cash equivalents balance exceeds the federally insured limits.
−Removed: As of December 31, 2021, the Company has not
−Removed: experienced a loss on its accounts for which it exceeds federally insured deposit limits, and does not expect a loss to
−Removed: On December 31, 2021, the cash equivalents include $ 60,021 of investments in money market funds.
+Added: The Company considers all highly liquid securities readily convertible
+Added: to cash that mature within three months or less from the original date of purchase to be cash equivalents.
+Added: Financial instruments that
+Added: potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents.
+Added: Cash and cash equivalents
+Added: are held by financial institutions and are federally insured up to certain limits.
+Added: At times, the Company’s cash and cash equivalents
+Added: balance exceeds the federally insured limits.
+Added: As of December 31, 2022, the Company has not experienced a loss on its accounts for which
+Added: it exceeds federally insured deposit limits, and does not expect a loss to occur.
Accounts Receivable
−Removed: In the normal course of business, the Company
−Removed: provides credit to its customers and performs credit evaluations of these customers.
−Removed: The Company periodically reviews accounts receivables
−Removed: for doubtful accounts on a customer-by-customer basis and established an allowance to reserve for balances that are deemed uncollectible.
−Removed: The allowance for doubtful accounts was $6,016 as of December 31, 2021, and 2020.
+Added: In the normal course of business, the Company provides credit to its
+Added: customers and performs credit evaluations of these customers.
+Added: The Company periodically reviews accounts receivables for doubtful accounts
+Added: on a customer-by-customer basis and established an allowance to reserve for balances that are deemed uncollectible.
+Added: The allowance for
+Added: doubtful accounts was $ 6,016 as of December 31, 2022, and 2021.
Investments in marketable securities
+Added: The Company accounts for its investments in debt securities in accordance
+Added: with Accounting Standards Codification (“ASC”) 320, Investments — Debt Securities (“ASC 320”).
+Added: Debt securities, which are comprised of investments in U.S.
+Added: Treasury Securities, are measured at fair value, based on quoted market prices.
+Added: As the Company has classified its investments in debt securities as available-for-sale, the Company recognizes all unrealized gains and
+Added: losses in other comprehensive income, net of tax, and recognizes all realized gains and losses in net income/loss within the Company’s
+Added: consolidated statement of operations and comprehensive loss.
The Company accounts for its investments in equity securities in accordance
with ASC 321, Investments — Equity Securities (“ASC 321”).
−Removed: Equity investments, which are comprised
−Removed: of investments in mutual funds shares, are measured at fair value, based on quoted market prices, with all gains and losses reported in
−Removed: the Company’s statement of operations.
−Removed: We may sell our equity securities in response to changes in interest rates, risk/reward characteristics,
−Removed: liquidity needs or other factors.
−Removed: Inventory consists of finished goods, work-in-process
−Removed: and raw materials and is valued at the lower of cost or net realizable value, determined by the first-in, first-out (“FIFO”)
−Removed: As the Company manufactures the finished goods and work-in-process materials, overhead costs are included in inventory.
−Removed: evaluates the carrying cost of finished goods, work-in-process and raw materials items.
−Removed: To the extent that such costs exceed future demand
−Removed: estimates and /or exhibit historical turnover at rates less than current inventory levels, the Company reduces the carrying value of the
−Removed: applicable inventories.
+Added: Equity securities, which are comprised of
+Added: investments in mutual funds shares, are measured at fair value, based on quoted market prices, with all gains and losses reported in net
+Added: income/loss within the Company’s consolidated statement of operations and comprehensive loss.
+Added: The Company may sell its debt or equity securities in response to changes
+Added: in interest rates, risk/reward characteristics, liquidity needs or other factors.
+Added: Inventory consists of finished goods, work-in-process and raw materials
+Added: and is valued at the lower of cost or net realizable value, determined by the first-in, first-out (“FIFO”) method.
+Added: Company manufactures the finished goods and work-in-process materials, overhead costs are included in inventory.
+Added: The Company evaluates
+Added: the carrying cost of finished goods, work-in-process and raw materials items.
+Added: To the extent that such costs exceed future demand estimates
+Added: and /or exhibit historical turnover at rates less than current inventory levels, the Company reduces the carrying value of the applicable
Inventory consisted of the following:
2 unchanged sentences
Total inventory
+Added: In December of 2022, the Company performed a detailed evaluation of
+Added: its inventory and determined $ 79,011 was obsolete.
+Added: As such, the Company has written off this inventory as of December 31, 2022.
Property and Equipment
−Removed: Property and equipment are recorded at cost and
−Removed: depreciated over the estimated useful lives of the related assets using the straight-line method.
−Removed: Lab equipment is depreciated over
−Removed: a five-year period.
+Added: Property and equipment are recorded at cost and depreciated over the
+Added: estimated useful lives of the related assets using the straight-line method.
+Added: Lab and office equipment are depreciated over a five-year period.
Leasehold improvements are depreciated over the shorter of the useful life and the term of the lease.
−Removed: are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from
−Removed: the balance sheet and any resulting gains or losses are included in the statement of operations in the period of disposals.
+Added: When assets are retired or otherwise
+Added: disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the balance sheet and any
+Added: resulting gains or losses are included in the consolidated statement of operations and comprehensive loss in the period of disposals.
Long-lived Assets
10 unchanged sentences
Revenue Recognition
−Removed: The Company’s revenue is generated primarily
−Removed: from the sale of products and research services.
−Removed: Product revenue primarily consists of sales of genetic sequencing equipment and sequencing
−Removed: reagent kits.
+Added: The Company’s revenue is generated primarily from the sale of
+Added: products and research services.
+Added: Product revenue primarily consists of sales of genetic sequencing equipment and sequencing reagent kits.
Research service revenue primarily consists of revenue generated from gene sequencing services and grants.
−Removed: The Company recognizes revenue in accordance with
−Removed: Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”).
−Removed: ASC 606, the Company recognizes revenue when control of its products and services is transferred to its customers in an amount that reflects
−Removed: the consideration the Company expects to receive from its customers in exchange for those products and services.
−Removed: To determine the appropriate
−Removed: amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs a five-step process.
−Removed: This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the
−Removed: contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when (or
−Removed: as) the performance obligations have been satisfied.
−Removed: A performance obligation is considered distinct from other obligations in a contract
−Removed: when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer
−Removed: and is separately identified in the contract.
−Removed: The Company only applies the five-step process to contracts when it is probable that the
−Removed: entity will collect consideration it expects to be entitled to in exchange for the goods or services it transfers to the customer.
−Removed: The Company evaluates contingent payments to estimate
−Removed: the amount which is not probable of a material reversal to include in the transaction price using the most likely amount method.
−Removed: payments that are not within the control of the Company, are not considered probable of being achieved until the contingencies are resolved.
−Removed: Revenue from product sales, including customized
−Removed: sequencing instruments and sequencing reagent kits and off-the-shelf consumables, is recognized generally upon delivery, which is when
−Removed: control of the product is deemed to be transferred.
+Added: The Company recognizes revenue in accordance with Accounting Standards
+Added: Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”).
+Added: Under ASC 606, the Company
+Added: recognizes revenue when control of its products and services is transferred to its customers in an amount that reflects the consideration
+Added: the Company expects to receive from its customers in exchange for those products and services.
+Added: To determine the appropriate amount of
+Added: revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs a five-step process.
+Added: process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract
+Added: price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when (or as) the
+Added: performance obligations have been satisfied.
+Added: A performance obligation is considered distinct from other obligations in a contract when
+Added: it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and
+Added: is separately identified in the contract.
+Added: The Company only applies the five-step process to contracts when it is probable that the entity
+Added: will collect consideration it expects to be entitled to in exchange for the goods or services it transfers to the customer.
+Added: The Company evaluates contingent payments to estimate the amount which
+Added: is not probable of a material reversal to include in the transaction price using the most likely amount method.
+Added: Future payments that are
+Added: not within the control of the Company, are not considered probable of being achieved until the contingencies are resolved.
+Added: Revenue from product sales, including customized sequencing instruments
+Added: and sequencing reagent kits and off-the-shelf consumables, is recognized generally upon delivery, which is when control of the product
+Added: is deemed to be transferred.
Revenue from gene sequencing services, using the tSMS platform, is
5 unchanged sentences
are sequential in nature and highly interrelated as they work together to generate sample-specific data.
−Removed: As the Company’s standard payment terms
−Removed: are less than one year, the Company has elected the practical expedient under ASC 606-10-32-18 to not assess whether a contract has a
−Removed: significant financing component.
+Added: As the Company’s standard payment terms are less than one year,
+Added: the Company has elected the practical expedient under ASC 606-10-32-18 to not assess whether a contract has a significant financing component.
The Company has elected to exclude sales tax from revenue.
−Removed: generally has no obligations for returns, refunds and other similar obligations and does not provide separate equipment warranties.
−Removed: Company recognized $ 16,484 and $ 50,588 in revenue from gene sequencing services for the years ended December 31, 2021, and 2020, respectively.
−Removed: The Company recognized $ 31,537 , and $ 0 in revenue from product sales for the years ended December 31, 2021, and 2020, respectively.
+Added: The Company generally has no obligations for returns, refunds and other similar
+Added: obligations and does not provide separate equipment warranties.
+Added: The Company recognized $ 0 and $ 16,484 in revenue from gene sequencing
+Added: services for the years ended December 31, 2022 and 2021, respectively.
+Added: The Company recognized $ 1,177 and $ 31,537 in revenue from product
+Added: sales for the years ended December 31, 2022 and 2021, respectively.
Grant Revenue
−Removed: The Company’s grant revenues are derived
−Removed: from research programs by various departments of the National Institute of Health (NIH Grants).
−Removed: Grants awarded to the Company for research and
−Removed: development by government entities are outside the scope of ASC 606 guidance.
−Removed: This is because these granting entities are not considered
−Removed: to be customers and are not receiving reciprocal value for their grant support provided to the Company.
−Removed: These grants provide the Company
−Removed: with payments for certain types of expenditures in return for research and development activities over a contractually defined period.
−Removed: The Company recognizes NIH Grants revenue as reimbursable grant costs
−Removed: are incurred up to pre-approved award limits within the budget period.
−Removed: The costs associated with these reimbursements are reflected as
−Removed: a component of research and development expense in the accompanying consolidated statements of operations.
−Removed: In the years ended December
−Removed: 31, 2021, and 2020, the Company earned grant revenue of $ 161,974 and $ 278,907 , respectively.
−Removed: The Company utilizes the liability method of accounting
−Removed: for income taxes as required by ASC 740, Income Taxes .
−Removed: Under this method, deferred tax assets and liabilities are determined based
−Removed: on differences between financial reporting and the tax basis of assets and liabilities as well as net operating loss carryforwards and
−Removed: tax credits and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse.
−Removed: tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized.
−Removed: Currently, there
−Removed: is no provision for income taxes, as the Company has incurred operating losses to date, and a full valuation allowance has been provided
−Removed: on the net deferred tax assets.
−Removed: The Company determines whether it is more likely
−Removed: than not that a tax position will be sustained upon examination.
−Removed: If it is not more likely than not that a position will be sustained,
−Removed: none of the benefit attributable to the position is recognized.
+Added: The Company’s grant revenues are derived from research programs
+Added: by various departments of the National Institute of Health (“NIH”).
+Added: Grants awarded to SeqLL for research and development by government
+Added: entities are outside the scope of the contracts with customers and contributions guidance.
+Added: This is because these granting entities are
+Added: not considered to be customers and are not receiving reciprocal value for their grant support provided to the Company.
+Added: These grants provide
+Added: the Company with payments for certain types of expenditures in return for research and development activities over a contractually defined
+Added: The Company recognizes NIH grant revenue as reimbursable grant costs
+Added: that are incurred up to pre-approved award limits within the budget period.
+Added: The costs associated with these reimbursements are reflected
+Added: as a component of research and development expense in the accompanying consolidated statements of operations and comprehensive loss.
+Added: the years ended December 31, 2022, and 2021, the Company recognized grant revenue of $ 77,482 and $ 161,974 , respectively.
+Added: The Company utilizes the liability method of accounting for income
+Added: taxes as required by ASC 740, Income Taxes .
+Added: Under this method, deferred tax assets and liabilities are determined based on differences
+Added: between financial reporting and the tax basis of assets and liabilities as well as net operating loss carryforwards and tax credits and
+Added: are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse.
+Added: Deferred tax assets
+Added: are reduced by a valuation allowance if it is more likely than not that these assets may not be realized.
+Added: Currently, there is no provision
+Added: for income taxes, as the Company has incurred operating losses to date, and a full valuation allowance has been provided on the net deferred
+Added: The Company determines whether it is more likely than not that a tax
+Added: position will be sustained upon examination.
+Added: If it is not more likely than not that a position will be sustained, none of the benefit
+Added: attributable to the position is recognized.
The tax benefit to be recognized for any tax position that meets the more-likely-than-not
1 unchanged sentence
The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.
−Removed: The Company has no accruals for interest or penalties
−Removed: related to income tax matters.
+Added: The Company has no accruals for interest or penalties related to income
Tax years subsequent to 2019 remain open to examination by federal and state tax authorities.
Stock-based Compensation
−Removed: The Company’s share-based compensation program
−Removed: grants awards include stock options and restricted stock awards.
−Removed: The fair value of stock option grants is estimated as of the date of
−Removed: the grant using the Black-Scholes option pricing model.
−Removed: The fair value of restricted stock awards is based on the fair value of the Company’s
−Removed: common stock on the date of the grant.
+Added: The Company’s share-based compensation program grants awards
+Added: include stock options and restricted stock awards.
+Added: The fair value of stock option grants is estimated as of the date of the grant using
+Added: the Black-Scholes option pricing model.
+Added: The fair value of restricted stock awards is based on the fair value of the Company’s common
+Added: stock on the date of the grant.
The fair value of the stock-based awards are then expensed over the requisite service period, generally
the vesting period, for each award.
−Removed: The Company’s expected stock price volatility
−Removed: assumption is based on the volatility of comparable public companies.
−Removed: The expected term of a stock option granted to employees and directors
−Removed: (including non-employee directors) is based on the average of the contractual term (generally 10 years) and the vesting period.
−Removed: For non-employee
−Removed: options, the expected term is the contractual term.
+Added: The Company’s expected stock price volatility assumption is based
+Added: on the volatility of comparable public companies.
+Added: The expected term of a stock option granted to employees and directors (including non-employee
+Added: directors) is based on the average of the contractual term (generally 10 years) and the vesting period.
+Added: For non-employee options, the
+Added: expected term is the contractual term.
The risk-free interest rate is based on the yield of U.S.
−Removed: Treasury securities consistent
−Removed: with the life of the option.
+Added: Treasury securities consistent with the
+Added: life of the option.
No dividend yield was assumed as the Company does not pay dividends on its common stock.
−Removed: The Company recognizes
−Removed: forfeitures related to stock-based awards as they occur.
−Removed: The Company has periodically granted stock options
−Removed: and restricted stock awards to consultants for services, pursuant to the Company’s stock plans at the fair market value on the respective
−Removed: dates of grant.
−Removed: Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would be
−Removed: For awards granted to consultants and non-employees, compensation expense is recognized over the vesting period of the awards,
−Removed: which is generally the period services are rendered by such consultants and non-employees.
−Removed: The Company did not grant any stock options during
−Removed: the year ended December 31, 2020.
−Removed: The assumptions used in determining the fair value of share-based awards granted in 2021 are as follows:
+Added: The Company recognizes forfeitures
+Added: related to stock-based awards as they occur.
+Added: The Company has periodically granted stock options and restricted stock
+Added: awards to consultants for services, pursuant to the Company’s stock plans at the fair market value on the respective dates of grant.
+Added: Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would be cancelled.
+Added: awards granted to consultants and non-employees, compensation expense is recognized over the vesting period of the awards, which is generally
+Added: the period services are rendered by such consultants and non-employees.
+Added: The assumptions used in determining the fair value of share-based awards
+Added: granted in 2022 and 2021 are as follows:
Risk-free interest rate
Expected option life
+Added: 6 – 6.1 years
Expected dividend yield
1 unchanged sentence
Research and Development Expenses
−Removed: The Company expenses all research and development
−Removed: costs as incurred.
−Removed: Included in research and development costs are wages, stock-based compensation and benefits of employees and other
−Removed: operational costs related to the Company’s research and development activities, including facility-related expenses and external
−Removed: costs of outside contractors engaged by the Company.
−Removed: The Company operates in a single business segment
−Removed: that includes the design, development and manufacturing of genetic analysis technologies.
−Removed: Derivative Instruments
−Removed: from time-to-time will issue warrants to its investors and accounts for warrant instruments as either equity-classified or liability-classified
−Removed: instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480, Distinguishing
−Removed: Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”).
−Removed: The assessment
−Removed: considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant
−Removed: to ASC 480, and meet all of the requirements for equity classification under ASC 718, Compensation – Stock Compensation (“ASC
−Removed: 718”) and ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the
−Removed: warrants could potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions
−Removed: for equity classification.
−Removed: date, the Warrants and Underwriter Warrants (see Note 9) were accounted for as equity as these instruments meet all of the requirements
−Removed: for equity classification under ASC 815 and ASC 718.
+Added: The Company expenses all research and development costs as incurred.
+Added: Included in research and development costs are wages, stock-based compensation and benefits of employees and other operational costs related
+Added: to the Company’s research and development activities, including facility-related expenses and external costs of outside contractors
+Added: engaged by the Company.
+Added: The Company operates in a single business segment that includes the
+Added: design, development and manufacturing of genetic analysis technologies.
+Added: In the first quarter of 2022, the Company adopted Accounting Standards
+Added: Update (“ASU”) No.
+Added: 2016-02, Leases (Topic 842) which had no impact on the Company’s financial statements
+Added: upon adoption.
+Added: The Company assesses its contracts at inception to determine whether the contract contains a lease, including evaluation
+Added: of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time.
+Added: The Company recognizes
+Added: right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount
+Added: rate corresponding to the Company’s incremental borrowing rate and amortizing over the remaining terms of the leases.
+Added: Company accounts for the leases of less than 12 months as short-term leases.
Net Loss per Share
−Removed: Basic net loss per share is computed by dividing
−Removed: the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially
−Removed: dilutive securities if their effect is antidilutive.
−Removed: Diluted net loss per share is computed by dividing the net loss by the weighted average
−Removed: number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock
−Removed: and if-converted methods.
−Removed: Dilutive common stock equivalents are comprised of convertible preferred stock, convertible promissory notes,
−Removed: options outstanding under the Company’s stock option plan and warrants.
−Removed: For all periods presented, there is no difference in the
−Removed: number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.
−Removed: The following potential shares of common stock
−Removed: were not considered in the computation of diluted net loss per share as their effect would have been antidilutive:
−Removed: Convertible preferred stock
−Removed: Convertible promissory notes
+Added: Basic net loss per share is computed by dividing the net loss by the
+Added: weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities
+Added: if their effect is antidilutive.
+Added: Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares
+Added: of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted
+Added: Dilutive common stock equivalents are comprised of options outstanding under the Company’s stock option plan and warrants.
+Added: For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion
+Added: of the potentially dilutive securities would be antidilutive.
+Added: The following potential shares of common stock were not considered
+Added: in the computation of diluted net loss per share as their effect would have been antidilutive:
Stock options
1 unchanged sentence
Recently Issued Accounting Standards
−Removed: In August 2020, FASB issued ASU 2020-06, Debt—Debt with Conversion
−Removed: and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):
−Removed: for Convertible Instruments and Contracts in an Entity’s Own Equity, which, among other things, provides guidance on how to account
−Removed: for contracts on an entity’s own equity.
−Removed: This ASU eliminates the beneficial conversion and cash conversion accounting models for
−Removed: convertible instruments.
−Removed: It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted
−Removed: for as derivatives because of specific settlement provisions.
−Removed: In addition, this ASU modifies how particular convertible instruments and
−Removed: certain contracts that may be settled in cash or shares impact the diluted EPS computation.
−Removed: The amendments in this ASU are effective for
−Removed: the public companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years.
−Removed: Early adoption
−Removed: is permitted, but no earlier than fiscal years beginning after December 15, 2020.
−Removed: The Company is currently evaluating the impact of ASU
−Removed: 2020-06 on its consolidated financial statements.
−Removed: The Company adopted this standard on January 1, 2022, for which, there was no material
−Removed: impact to the Company’s consolidated financial statements.
−Removed: In February 2016, the Financial Accounting Standards
−Removed: Board (“FASB”) issued Accounting Standards Update (“ASU”) No.
−Removed: 2016-02, Leases (“ASU 2016-02”) which
−Removed: establishes new accounting and disclosure requirements for leases.
−Removed: 2016-02 requires recognition in the statement of operations
−Removed: of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis.
−Removed: ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows.
−Removed: Disclosures are required
−Removed: to provide the amount, timing and uncertainty of cash flows arising from leases.
−Removed: The Company will adopt the provisions of ASU 2016-02
−Removed: in the quarter beginning January 1, 2022, using the modified retrospective approach and will record right of use assets and lease liabilities
−Removed: on its consolidated balance sheet for the leases with terms in excess of one year.
−Removed: A modified retrospective transition approach is required
−Removed: for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented
−Removed: in the financial statements, with certain practical expedients available.
−Removed: The Company adopted this standard on January 1, 2022, for which,
−Removed: there was no material impact to the Company’s consolidated financial statements.
−Removed: The Company does not believe that any other recently
−Removed: issued but not yet effective accounting pronouncements will have a material effect on the accompanying consolidated financial statements.
+Added: In June 2016, the Financial Accounting Standards Board (“FASB”)
+Added: issued Accounting Standards Update (“ASU”) No.
+Added: 2016-13, Financial Instruments-Credit Losses:
+Added: Measurement of Credit Losses
+Added: on Financial Instruments.
+Added: ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets.
+Added: In April 2019,
+Added: the FASB issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit
+Added: Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13.
+Added: The guidance is effective for fiscal
+Added: years beginning after December 15, 2022.
+Added: The Company has adopted ASU 2016-13 effective January 1, 2023, for which, there was an immaterial
+Added: impact on the Company’s financial statements and financial statement disclosures.
+Added: The Company does not believe that any other recently issued accounting
+Added: pronouncements had or will have a material effect on its consolidated financial statements.
Note 3 – Property and Equipment, net
−Removed: Property and equipment are recorded at historical
−Removed: cost and consist of the following:
+Added: Property and equipment are recorded at historical cost and consist
+Added: of the following:
Lab equipment
2 unchanged sentences
accumulated depreciation
−Removed: Depreciation expense amounted to $ 86,444 and $ 108,759
−Removed: for the years ended December 31, 2021, and 2020, respectively.
+Added: Depreciation expense amounted to $ 87,937 and $ 86,444 for the years
+Added: ended December 31, 2022, and 2021, respectively.
Note 4 – Accrued Expenses
1 unchanged sentence
Accrued interest
−Removed: 5 – Fair Value Measurements
−Removed: The accounting
−Removed: guidance defines fair value, establishes a consistent framework for measuring fair value and requires disclosure for each major asset
−Removed: and liability category measured at fair value on either a recurring or non-recurring basis.
−Removed: Fair value is defined as an exit price, representing
−Removed: the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.
−Removed: As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in
−Removed: pricing an asset or liability.
−Removed: As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value
−Removed: hierarchy, which prioritizes the inputs used in measuring fair value as follows:
−Removed: Observable inputs such
−Removed: as quoted prices in active markets.
−Removed: Inputs, other than
−Removed: the quoted prices in active markets that are observable either directly or indirectly.
−Removed: Unobservable inputs
−Removed: in which there is little or no market data, which require the reporting entity to develop its own assumptions.
−Removed: following table summarizes fair value measurements by level on December 31, 2021 of the Company’s assets measured at fair
−Removed: value on a recurring basis:
+Added: Accrued bonuses
+Added: Note 5 – Fair Value Measurements
+Added: The accounting guidance defines fair value, establishes a consistent
+Added: framework for measuring fair value and requires disclosure for each major asset and liability category measured at fair value on either
+Added: a recurring or non-recurring basis.
+Added: Fair value is defined as an exit price, representing the amount that would be received to sell an
+Added: asset or paid to transfer a liability in an orderly transaction between market participants.
+Added: As such, fair value is a market-based measurement
+Added: that should be determined based on assumptions that market participants would use in pricing an asset or liability.
+Added: As a basis for considering
+Added: such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring
+Added: fair value as follows:
+Added: Observable inputs such as quoted prices in active markets.
+Added: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.
+Added: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
+Added: The following table summarizes fair value measurements by level on
+Added: December 31, 2022 of the Company’s assets measured at fair value on a recurring basis:
Fair Value Measurements Using
+Added: government and agency obligations
+Added: The following table summarizes fair value measurements by level on
+Added: December 31, 2021 of the Company’s assets measured at fair value on a recurring basis:
+Added: Fair Value Measurements Using
Cash and cash equivalents
−Removed: Marketable securities
Total financial assets
−Removed: determines fair value for cash equivalents and marketable securities with Level 1 inputs through the reference to the quoted market prices.
−Removed: no assets or liabilities measured at fair value on December 31, 2020.
−Removed: below presents the changes in Level 3 liabilities measured at fair value on a recurring basis (See Note 8).
−Removed: Convertible Notes
+Added: The Company determines fair value for cash equivalents and marketable
+Added: securities with Level 1 inputs through the reference to the quoted market prices.
+Added: The table below presents the 2021 changes in Level 3 liabilities measured
+Added: at fair value on a recurring basis (See Note 8).
Balance at December 31, 2020
4 unchanged sentences
Balance at December 31, 2021
−Removed: date, the Amended Notes were converted into 641,895 shares of common stock (see Note 8).
−Removed: The interest expense of $ 89,239 for the period
−Removed: between the date of the Conversion Agreements related to the Amended Notes (see Note 7) and December 31, 2021, is included in the change
−Removed: in fair value of the Amended Notes.
−Removed: no assets or liabilities measured at fair value on a non-recurring basis during the years ended December 31, 2021, and 2020.
+Added: At the IPO date, the Amended Notes were converted into 641,895 shares
+Added: of common stock (see Note 8).
+Added: The interest expense of $ 89,239 for the period between the date of the Conversion Agreements related to
+Added: the Amended Notes (see Note 8) and December 31, 2021, is included in the change in fair value of the Amended Notes.
+Added: There are no assets or liabilities measured at fair value on a non-recurring
+Added: basis during the years ended December 31, 2022, and 2021.
+Added: The carrying values of financial instruments such as accounts receivable,
+Added: net, other receivables, accounts payable, and accrued expenses approximated fair value as of December 31, 2022 and December 31, 2021 due
+Added: to their short-term maturities.
+Added: The carrying value of the Company’s Non-Convertible Promissory Note approximated its fair value
+Added: as of December 31, 2022 and December 31, 2021.
Note 6 – Stock Option Plan
−Removed: The Company’s 2014 Equity Incentive Plan
−Removed: (the “2014 Plan”) permits the grant of options for its common stock and shares of common stock to its employees, board members
−Removed: and consultants for up to 3,500,000 shares.
+Added: The Company’s 2014 Equity Incentive Plan (the “2014 Plan”)
+Added: permits the grant of options for its common stock and shares of common stock to its employees, board members and consultants for up to
+Added: 3,500,000 shares.
As of December 31, 2022, there were 1,496,081 shares available for
6 unchanged sentences
is a change in control (as defined by the 2014 Plan).
−Removed: The weighted average grant date fair value of options granted in 2021 was $ 1.15
−Removed: No option awards were granted in 2020.
−Removed: The stock option activity for the year ended December
−Removed: 31, 2021 is as follows:
+Added: The weighted average grant date fair value of options granted in 2022 and 2021 were
+Added: $ 0.89 and $ 1.15 , respectively, per share.
+Added: The stock option activity for the year ended December 31, 2022 is as
Exercise Price
Outstanding as of December 31, 2021
−Removed: Cancelled/Forfeited
Outstanding of December 31, 2022
3 unchanged sentences
As of December 31, 2022,
−Removed: there was $ 2,772 of unrecognized compensation expense related to unvested share-based compensation awards, which will be recognized over
−Removed: approximately 1.3 years .
+Added: there was $ 710,812 of unrecognized compensation expense related to unvested share-based compensation awards, which will be recognized
+Added: over approximately 1.5 years.
Note 7 – Related Party Transactions
−Removed: As of December 31, 2021, and 2020, the outstanding amount due to Daniel
−Removed: Jones, the Company’s Chief Executive Officer, was $ 0 and $ 26,000 , respectively, relating to a series of non-interest-bearing demand
−Removed: The loans were repaid in the year ended December 31, 2021, with a portion of the net proceeds from the IPO.
−Removed: Daniel Jones also made non-interest-bearing demand loans to the Company
−Removed: in the amounts of $ 90,000 and $ 50,000 on July 30, 2021 and August 20, 2021, respectively.
−Removed: Both loans were repaid in full with proceeds
−Removed: from the IPO.
At December 31, 2022 and 2021, the Company had the following outstanding
−Removed: payables, which are included within the Company’s accounts payable above, to its preferred shareholders for past services:
−Removed: Floral Finance
+Added: payables, which are included within the Company’s accounts payable above, to affiliated parties for past services:
Genomic Diagnostic Technologies
1 unchanged sentence
Laurent Realty, Inc.
−Removed: Stonemill Center
Total related party payables
−Removed: Laurent, a former
−Removed: member of the Company’s board of directors, relatives of Mr.
−Removed: Laurent and entities controlled by the St.
−Removed: Laurent family are controlling
−Removed: shareholders of the Company.
−Removed: These entities are all St.
−Removed: Laurent family-owned entities and are therefore related parties:
−Removed: Laurent Realty,
−Removed: and Genomic Diagnostic Technologies assisted the Company by previously providing corporate accounting support;
−Removed: Laurent Institute,
−Removed: a 501C-3 company, provided bioinformatics specialist support for certain sequencing services;
−Removed: Stonemill Center assisted the Company by
−Removed: paying for certain out of pocket expenses incurred by William C.
−Removed: Laurent in his former role as Chairman of the Board for the Company;
−Removed: and William C.
−Removed: Laurent as the former Chairman of the Board accrued Director’s compensation was paid by the Company prior to
−Removed: December 31 ,2021.
−Removed: The Company issued convertible
−Removed: notes and promissory notes to the related parties (see Note 8).
+Added: The above entities are affiliated with (1) William C.
+Added: a former member of the Company’s board of directors, (2) relatives of Mr.
+Added: Laurent or (3) entities controlled by the St.
+Added: family, who are controlling shareholders of the Company.
+Added: Laurent Realty, Inc.
+Added: and Genomic Diagnostic Technologies assisted the Company
+Added: by previously providing corporate accounting support;
+Added: Laurent Institute, a non-for-profit company, provided bioinformatics specialist
+Added: support for certain sequencing services.
+Added: During 2021, Daniel Jones, the Company’s Chief Executive Officer,
+Added: made non-interest-bearing demand loans to the Company in the amounts of $ 90,000 and $ 50,000 .
+Added: Both loans were repaid in full with proceeds
+Added: from the IPO.
Note 8 – Notes Payable
1 unchanged sentence
“Convertible Notes”) through April 8, 2019, with certain preferred stockholders amounting to $ 905,000 .
−Removed: The Convertible Notes had a one-year term
−Removed: and accrued interest at 10 % per annum.
−Removed: The Convertible Notes were convertible at the lower of $ 3.10 per share or a 20 % discount to the
−Removed: share price paid by the purchasers of equity securities in the Company’s next Qualified Financing, as defined in the convertible
−Removed: note agreement.
−Removed: From April 29, 2019, to April 29, 2020, the Company entered
−Removed: into a series of non-convertible promissory notes (the “Promissory Notes”) with a certain preferred stockholder amounting
−Removed: to $ 1,375,000 .
+Added: The Convertible Notes
+Added: had a one-year term and accrued interest at 10 % per annum.
+Added: The Convertible Notes were convertible at the lower of $ 3.10 per share or a
+Added: 20 % discount to the share price paid by the purchasers of equity securities in the Company’s next Qualified Financing, as defined
+Added: in the convertible note agreement.
+Added: From April 29, 2019, to April 29, 2020, the Company entered into a
+Added: series of non-convertible promissory notes (the “Promissory Notes”) with a certain preferred stockholder amounting to $ 1,375,000 .
The Promissory Notes had a one-year term with interest accruing at 10 % per annum.
−Removed: In November and December 2020, the Company issued senior secured
−Removed: convertible promissory notes (included in the Convertible Notes) to a third-party investor amounting to $ 200,000 .
−Removed: These notes accrued
−Removed: interest at 10 % per annum, were to be repaid at the earlier of December 31, 2022, or the Company’s next qualified financing of a
−Removed: minimum of $ 7.5 million (as defined in the notes agreement), or convertible at $ 3.75 per share.
+Added: In November and December 2020, the Company issued senior secured convertible
+Added: promissory notes to a third-party investor amounting to $ 200,000 .
+Added: These notes accrued interest at 10 % per annum, were to be repaid at
+Added: the earlier of December 31, 2022 , or the Company’s next qualified financing of a minimum of $ 7.5 million (as defined in the notes
+Added: agreement) and were convertible at $ 3.75 per share.
On December 31, 2020, the Company issued a non-convertible promissory
Laurent Investments LLC amounting to $ 426,020 due July 31, 2022 , bearing 10 % interest per annum in exchange for the accrued
−Removed: interest on all their notes outstanding.
−Removed: From January to March 2021, the
−Removed: Company issued senior secured convertible promissory notes to investors for total proceeds of $ 250,000 .
−Removed: The Convertible Notes accrued
−Removed: interest at 10 % per annum, matured at the earlier of December 31, 2022, or the Company’s next qualified equity offering of
−Removed: a minimum of $ 7.5 million, and were convertible at $ 3.75 per share.
−Removed: 3, 2021, the preferred stockholder and the holder of $ 2,910,710 in the Convertible Notes and Promissory Notes of the Company granted
−Removed: the Company an extension on all their notes to be repaid on or before July 31, 2022.
−Removed: This amendment was accounted for on a prospective
−Removed: basis under the troubled debt restructuring guidance.
−Removed: 2021, the Company entered into a series of agreements with the noteholders to automatically convert $ 786,730 in outstanding Promissory
−Removed: Notes and $ 1,305,000 in Convertible Notes (together, “Amended Notes”), to common stock upon the closing of the IPO (“Conversion
−Removed: Agreements”), of which $ 1,552,683 is held by St.
+Added: interest on all its notes of the Company outstanding through that date.
+Added: From January to March 2021, the Company issued senior secured convertible
+Added: promissory notes to investors for total proceeds of $ 250,000 .
+Added: The Convertible Notes accrued interest at 10 % per annum, matured at the
+Added: earlier of December 31, 2022 , or the Company’s next qualified equity offering of a minimum of $ 7.5 million, and were convertible
+Added: at $ 3.75 per share.
+Added: On February 3, 2021, the preferred stockholder and the holder of $ 2,910,710
+Added: in the Convertible Notes and Promissory Notes of the Company granted the Company an extension on all its notes of the Company to be repaid
+Added: on or before July 31, 2022.
+Added: This amendment was accounted for on a prospective basis under the troubled debt restructuring guidance.
+Added: In March 2021, the Company entered into a series of agreements with
+Added: the noteholders to automatically convert $ 786,730 in outstanding Promissory Notes and $ 1,305,000 in Convertible Notes (together, “Amended
+Added: Notes”), to common stock upon the closing of the IPO (“Conversion Agreements”), of which $ 1,552,683 was held by St.
Laurent Investments, LLC and its affiliates.
−Removed: Under the terms of the conversion
−Removed: agreements, $ 826,020 and $ 1,265,710 in Amended Notes were to be converted at the closing of the IPO based on the $ 3.75 and
−Removed: $ 3.10 conversion prices, respectively.
−Removed: Since the automatic conversion could result in a material benefit to the noteholders, this
−Removed: amendment was deemed substantive and was accounted for as an extinguishment of debt.
−Removed: Accordingly, the Company recognized a loss on extinguishment
−Removed: of debt totaling $ 934,257 in the consolidated statement of operations in March 2021, which represents the excess of the fair value
−Removed: of the Amended Notes totaling $ 3,118,235 over their carrying value of $ 2,183,978 .
−Removed: The Company elected the option to account for the
−Removed: Amended Notes at fair value, with the changes in fair value recognized in the statement of operations.
−Removed: The fair value of the Amended Notes
−Removed: was estimated using probability weighted expected payouts under various settlement scenarios, discounted to their present value based
−Removed: on the estimated effective rate of return.
−Removed: 29, 2021, the Company entered into an agreement with a noteholder to automatically convert an additional $ 50,000 in outstanding Amended
−Removed: Notes, including any accrued interest, to common stock upon the closing of the IPO at the conversion price of $ 3.75 per share.
−Removed: date, the Amended Notes automatically converted based on their original terms into 641,895 shares of common stock.
−Removed: value of the Amended Notes of $ 3,364,198 immediately prior to the conversion, less $ 141,884 cash payment related to the accrued
−Removed: interest, was reclassified into the additional paid in capital on the condensed consolidated balance sheet.
−Removed: The fair value of the Amended
−Removed: Notes at the conversion date was estimated based on the fair value of the common stock issued upon the conversion.
−Removed: recognized $ 195,962 loss due to the change in fair value of the Amended Notes between the amendment date and their conversion at
−Removed: the IPO date.
+Added: Under the terms of the conversion agreements, $ 826,020 and $ 1,265,710 in Amended Notes were
+Added: to be converted at the closing of the IPO based on the $ 3.75 and $ 3.10 conversion prices, respectively.
+Added: Since the automatic conversion
+Added: could result in a material benefit to the noteholders, this amendment was deemed substantive and was accounted for as an extinguishment
+Added: Accordingly, the Company recognized a loss on extinguishment of debt totaling $ 934,257 in the consolidated statement of operations
+Added: and comprehensive loss for the three months ended March 2021, which represented the excess of the fair value of the Amended Notes totaling
+Added: $ 3,118,235 over their carrying value of $ 2,183,978 .
+Added: The Company elected the option to account for the Amended Notes at fair value, with
+Added: the changes in fair value recognized in the statement of operations and comprehensive loss.
+Added: The fair value of the Amended Notes was estimated
+Added: using probability weighted expected payouts under various settlement scenarios, discounted to their present value based on the estimated
+Added: effective rate of return.
+Added: On April 29, 2021, the Company entered into an agreement with a noteholder
+Added: to automatically convert an additional $ 50,000 in outstanding Amended Notes, including any accrued interest, to common stock upon the
+Added: closing of the IPO at the conversion price of $ 3.75 per share.
+Added: At the IPO date, the Amended Notes automatically converted based on
+Added: their original terms into 641,895 shares of common stock.
+Added: The fair value of the Amended Notes of $ 3,364,198 immediately prior to the conversion,
+Added: less a $ 141,884 cash payment related to the accrued interest, was reclassified into the additional paid in capital on the consolidated
+Added: balance sheet.
+Added: The fair value of the Amended Notes at the conversion date was estimated based on the fair value of the common stock issued
+Added: upon the conversion.
+Added: The Company recognized $ 195,962 loss due to the change in fair value
+Added: of the Amended Notes between the amendment date and their conversion at the IPO date.
In October 2021, the Company entered into an agreement with St.
−Removed: Investments LLC to reduce the interest on $ 1,375,000 in the Promissory Note from 10 % to 5 % per year starting on October 1, 2021.
−Removed: Company accounted for this transaction as a modification on a prospective basis.
−Removed: In October 2021, the Company repaid $ 270,000 of
−Removed: the Promissory Notes to William C.
+Added: Investments LLC to reduce the interest on $ 1,375,000 principal amount of the Promissory Notes from 10 % to 5 % per year starting on October
+Added: The Company accounted for this transaction as a modification on a prospective basis.
+Added: In October 2021, the Company repaid $ 270,000 of the Promissory Notes
+Added: to William C.
St Laurent in cash.
−Removed: In connection with all the Convertible Notes and
−Removed: Promissory Notes issued during 2021 and 2020, the Company issued warrants to noteholders to purchase the total of 66,665 and 53,333 shares
−Removed: of the Company’s common stock, including 11,466 to the placement agent (see Note 10).
−Removed: The grant-date fair values of these warrants
−Removed: were immaterial.
+Added: In connection with all the Convertible Notes and Promissory Notes issued
+Added: during 2021 and 2020, the Company issued warrants to noteholders to purchase the total of 66,665 and 53,333 shares of the Company’s
+Added: common stock, including 11,466 to the placement agent (see Note 10).
+Added: The fair values of these warrants were immaterial at issuance.
+Added: In June 2022, the Company entered into an agreement with St.
+Added: Investments LLC to extend the maturity date of the $ 1,375,000 Promissory Note to July 31, 2024 .
+Added: The Company accounted for this transaction
+Added: as a modification on a prospective basis.
For the years ended December 31, 2022, and 2021, interest expense related
1 unchanged sentence
Note 9 – Preferred Stock
−Removed: The Company had outstanding preferred stock as
−Removed: of December 31, 2020:
−Removed: Issuance price
−Removed: Series A-1 Convertible Preferred Stock
−Removed: Series A-2 Convertible Preferred Stock
−Removed: Series A Preferred stock
−Removed: The Series A-1 Preferred Stock (“Series
−Removed: A-1”) and Series A-2 Preferred Stock (“Series A-2”) collectively the “Preferred Stock”, could be converted
−Removed: at any time at the election of the holder into common stock at an initial conversion price determined by dividing the Series A-1 original
−Removed: issue price of $ 0.59 , as amended, by the Series A-1 conversion price of $ 0.59 ;
−Removed: and the Series A-2 original issue price of $ 3.10 , as amended,
−Removed: by the Series A-2 conversion price of $ 3.10 ;
−Removed: both were subject to adjustment for stock splits, stock combinations and the like, and to
−Removed: a weighted-average adjustment for future issuances of common stock, warrants or rights to purchase common stock or securities convertible
−Removed: into common stock for a consideration per share that is less than the then-applicable conversion price, subject to certain exceptions
−Removed: listed in the Charter.
−Removed: The Preferred Stock was subject to automatic conversion
−Removed: upon (i) the closing of an initial public offering of the common stock at a price per share equal to at least $9.25 (as adjusted
−Removed: for any stock splits, stock dividends, combinations, subdivisions, recapitalization or the like) in an underwritten public offering in
−Removed: which the Company raised gross proceeds of at least $10 million or (ii) the consent of holders of at least a majority of the then-outstanding
−Removed: shares of Preferred Stock voting together as a single class.
−Removed: In connection with the IPO, all of the outstanding
−Removed: shares of the Company’s convertible preferred stock automatically converted into 3,130,622 shares of common stock.
+Added: The Series A-1 Preferred Stock (“Series A-1”) and Series
+Added: A-2 Preferred Stock (“Series A-2”) collectively the “Preferred Stock”, could be converted at any time at the election
+Added: of the holder into common stock at an initial conversion price determined by dividing the Series A-1 original issue price of $ 0.59 , as
+Added: amended, by the Series A-1 conversion price of $ 0.59 ;
+Added: and the Series A-2 original issue price of $ 3.10 , as amended, by the Series A-2
+Added: conversion price of $ 3.10 ;
+Added: both were subject to adjustment for stock splits, stock combinations and the like, and to a weighted-average
+Added: adjustment for future issuances of common stock, warrants or rights to purchase common stock or securities convertible into common stock
+Added: for a consideration per share that is less than the then-applicable conversion price, subject to certain exceptions listed in the Charter.
+Added: The Preferred Stock was subject to automatic conversion upon (i) the
+Added: closing of an initial public offering of the common stock at a price per share equal to at least $9.25 (as adjusted for any stock splits,
+Added: stock dividends, combinations, subdivisions, recapitalization or the like) in an underwritten public offering in which the Company raised
+Added: gross proceeds of at least $10 million or (ii) the consent of holders of at least a majority of the then-outstanding shares of Preferred
+Added: Stock voting together as a single class.
+Added: In connection with the IPO, all of the outstanding shares of the Company’s
+Added: convertible preferred stock automatically converted into 3,130,622 shares of common stock.
Note 10 – Common Stock Warrants
15 unchanged sentences
The warrants may be exercised for cash or through cashless exercise.
−Removed: The Company may redeem the outstanding warrants,
−Removed: in whole and not in part, at $0.001 per warrant if, after thirteen months from the issuance date, (i) the daily volume weighted average
−Removed: price of the Common Stock for each of 10 consecutive trading days (Measurement Period) exceeds $12.75 (subject to adjustment for forward
−Removed: and reverse stock splits, recapitalizations, stock dividends and the like after the issuance date), (ii) the average daily volume for
−Removed: such Measurement Period exceeds $1,000,000 per Trading Day and (iii) the holders of warrants are not in possession of any information
−Removed: that constitutes, or might constitute, material non-public information which was provided by the Company, any of its Subsidiaries, or
−Removed: any of their officers, directors, employees, agents or Affiliates.
+Added: The Company may redeem the outstanding warrants, in whole and not in
+Added: part, at $0.001 per warrant if, after thirteen months from the issuance date, (i) the daily volume weighted average price of the Common
+Added: Stock for each of 10 consecutive trading days (Measurement Period) exceeds $12.75 (subject to adjustment for forward and reverse stock
+Added: splits, recapitalizations, stock dividends and the like after the issuance date), (ii) the average daily volume for such Measurement Period
+Added: exceeds $1,000,000 per Trading Day and (iii) the holders of warrants are not in possession of any information that constitutes, or might
+Added: constitute, material non-public information which was provided by the Company, any of its Subsidiaries, or any of their officers, directors,
+Added: employees, agents or Affiliates.
Pursuant to the Underwriting Agreement, on August 31, 2021, and September
12 unchanged sentences
Issuance Date
−Removed: Number of Shares Issuable Upon Exercise of Outstanding Warrants
−Removed: Exercise Price
−Removed: Expiration Date
+Added: During the year ended December 31, 2022, warrants to purchase 5,211
+Added: shares of common stock with an exercise price of $ 3.10 expired.
Note 11 – Marketable Securities
−Removed: The cost and fair value of marketable securities were $ 5,976,442 and
−Removed: $ 5,933,364 as of December 31, 2021, respectively, resulting in $ 43,078 unrealized loss.
−Removed: The Company’s investment income amounted
−Removed: to $ 36,463 and $ 0 for the years ended December 31, 2021, and 2020, respectively, included in the investment income on the consolidated
−Removed: statement of operations.
−Removed: Note 12 – PPP Loan
+Added: The cost and fair value of marketable securities, which are available-for-sale
+Added: debt securities, were $ 4,013,563 and $ 4,036,014 as of December 31, 2022, respectively, resulting in a $ 22,451 unrealized gain included
+Added: in the other comprehensive income for the year ended December 31, 2022.
+Added: As of December 31, 2022, the contractual maturities for all available-for-sale
+Added: debt securities were less than one year .
+Added: Additionally, the Company recognized a net realized loss of $ 51,816
+Added: on marketable equity securities for the year ended December 31, 2022.
+Added: The cost and fair value of marketable equity securities were $ 5,976,442
+Added: and $ 5,933,364 as of December 31, 2021, respectively, resulting in $ 43,078 unrealized loss included in the consolidated statement
+Added: of operations and comprehensive loss for the year ended December 31, 2021.
+Added: The Company’s interest and dividend income amounted to $ 44,879
+Added: and $ 36,463 for the years ended December 31, 2022, and 2021, respectively.
+Added: The Company has not recognized any impairment in its financial statements
+Added: related to its marketable securities.
+Added: Note 12 – Paycheck Protection Program
On May 5, 2021, and May 7, 2020, the Company applied for and received
−Removed: a loan for $ 190,100 in each year in connection with the Paycheck Protection Program (“PPP”) pursuant to the CARES Act that
+Added: loans for $ 190,100 in each year in connection with the Paycheck Protection Program (“PPP”) pursuant to the CARES Act that
was signed into law on March 27, 2020.
−Removed: The loans have a term of 5 years, are unsecured, and are guaranteed
−Removed: by the Small Business Administration.
−Removed: The loans bear interest at one percent per annum, with the first six months of interest and principal
−Removed: Some or all of the loans may be forgiven if at least 60 % of the loans’ proceeds are used by the Company to cover payroll
−Removed: costs, including benefits, and if the Company maintains its employment and compensation within certain parameters during the period following
−Removed: the loans’ origination dates and comply with other relevant conditions.
−Removed: The Company elected to account for the PPP loans
−Removed: as in-substance government grants by applying the guidance in IAS 20 by analogy based on the assessment that it is probable that
−Removed: it will meet both (a) the eligibility criteria for a PPP loans, and (b) the loan forgiveness criteria for all or substantially
−Removed: all of the PPP loans.
−Removed: Under this guidance, the Company recorded the loan proceeds in Other income in the consolidated statement of operations
−Removed: for the years ended December 31, 2021 and 2020.
−Removed: As of December 31, 2021, the Company has been
−Removed: forgiven for its PPP loan that was incurred on May 7, 2020.
+Added: The loans had terms of 5 years, were unsecured and were guaranteed
+Added: by the Small Business Administration (“SBA”).
+Added: The loans bore interest at one percent per annum.
+Added: Loan payments were to be deferred
+Added: for borrowers who apply for loan forgiveness until the SBA remits the borrower’s loan forgiveness amount to the lender.
+Added: If a borrower
+Added: did not apply for loan forgiveness, payments were to be deferred 10 months after the end of the covered period for the borrower’s
+Added: loan forgiveness (between 8 and 24 weeks).
+Added: Some or all of the loans could be forgiven if at least 75 % of the loans’
+Added: proceeds were used by the Company to cover payroll costs, including benefits, and if the Company maintained its employment and compensation
+Added: within certain parameters during the period following the loans’ origination date and complied with other relevant conditions.
+Added: The Company elected to account for the PPP loans as an in-substance government
+Added: grants by applying the guidance in International Accounting Standards 20 by analogy based on the assessment that it is probable that it
+Added: will meet both (a) the eligibility criteria for a PPP loan, and (b) the loan forgiveness criteria for all or substantially all of the
+Added: Under this guidance, the Company recorded the loans’ proceeds in other income in the consolidated statement of operations
+Added: and comprehensive loss for the years in which the Company received a PPP Loan.
+Added: As of December 31, 2022, both of the PPP Loans referenced above were
Note 13 - Income Taxes
+Added: The Tax Cuts and Jobs Act (the “TCJA”) resulted in significant
+Added: changes to the treatment of research or experimental (“R&E”) expenditures under Section 174.
+Added: For tax years beginning after
+Added: December 31, 2021, taxpayers are required to capitalize and amortize all R&E expenditures that are paid or incurred in connection
+Added: with their trade or business which represent costs in the experimental or laboratory sense.
+Added: Specifically, costs for U.S.
+Added: activities must be amortized over five years and costs for foreign R&E activities must be amortized over 15 years;
+Added: both using a midyear
+Added: The Company has implemented this standard on January 1, 2022, noting that the impact on the Company’s consolidated financial
+Added: statements was immaterial.
The Company is subject to United States federal and Massachusetts state
11 unchanged sentences
During the years ended December 31, 2022 and 2021, the
−Removed: valuation allowance increased by approximately $ 1.2 million and $ 0.4 million, respectively.
−Removed: As of December 31, 2021, the Company did
−Removed: not maintain any foreign subsidiaries and did not have previously deferred foreign earnings subject to the transition tax.
−Removed: income tax benefit differs from the amount of income tax determined by applying the U.S.
−Removed: federal income tax rate to pretax income for
−Removed: the years ended December 31, 2021 and 2020 due to the following:
+Added: valuation allowance increased by approximately $ 1.2 million in both years.
+Added: As of December 31, 2022, the Company did not maintain any foreign
+Added: subsidiaries and did not have previously deferred foreign earnings subject to the transition tax.
+Added: The income tax benefit differs from the amount of income tax determined
+Added: by applying the U.S.
+Added: federal income tax rate to pretax income for the years ended December 31, 2022 and 2021 due to the following:
Computed “expected” tax benefit
4 unchanged sentences
Note 14 – Commitments and Contingencies
−Removed: In November 2014, the Company entered an office space lease in Woburn,
−Removed: Massachusetts (the “Lease”), which is considered the Company’s corporate headquarters, which was extended through November
−Removed: 30, 2020, and then subsequently further on a month-to-month basis until a notice by either of the parties.
−Removed: This lease is accounted for
−Removed: as a short-term lease with the expense recognized on a monthly basis when incurred.
−Removed: The rent expense for this lease was $ 216,860 and $ 180,732
−Removed: for the years ended December 31, 2021 and 2020, respectively.
−Removed: On September 15, 2018, the Company executed an
−Removed: agreement to guarantee of the obligations of John W.
−Removed: Kennedy, our Chief Financial Officer, on a lease for Mr.
−Removed: Kennedy’s housing.
−Removed: The annual rental amount due on the lease is $ 32,400 and was paid by Mr.
−Removed: Kennedy for each of the years ended December 31, 2021 and 2020.
−Removed: At December 31, 2021 and 2020, the Company had no obligations either anticipated or currently payable under the guarantee.
+Added: The Company’s office space lease in Woburn, Massachusetts (the
+Added: “Woburn Lease”) for the Company’s corporate headquarters was on a month-to-month basis since November 2020 and was terminated
+Added: in February 2022.
+Added: The rent expense for this lease was $ 14,239 and $ 216,860 for the years ended December 31, 2022 and 2021, respectively.
+Added: On February 2, 2022, the Company entered into a lease agreement for
+Added: approximately 15,638 square feet of its new corporate office space in Billerica, Massachusetts (the “Billerica Lease”).
+Added: Billerica Lease has a term of 92 months from its effective date and included access to certain additional office space until August 1,
+Added: In addition, the Company is required to share in certain taxes and operating expenses of the Billerica Lease.
+Added: The Billerica Lease is classified as an operating lease.
+Added: At the inception
+Added: date of the Billerica Lease, the Company recorded a right-of-use asset of $ 1,481,646 in operating lease right-of-use asset, as well as
+Added: a lease liability of $ 12,222 in current liabilities and $ 1,547,614 in long-term liabilities.
+Added: The operating lease right-of use asset is
+Added: less than that of the Company’s lease liabilities as of the lease inception date.
+Added: This is due to the fact that the Company as part
+Added: of the Billerica Lease was allowed certain tenant improvement allowances, which amounted to $ 78,190 at lease inception.
+Added: This lease liability
+Added: represented the net present value of future lease payments for the lease utilizing a discount rate of 5.98 %, which corresponded to the
+Added: Company’s incremental borrowing rate.
+Added: In August 2022, the Company received the tenant improvement allowance
+Added: from the landlord, which totaled approximately $ 312,758 .
+Added: This allowance covered the leasehold improvements to the Billerica space and
+Added: was accounted for as a reduction to the right-of-use asset.
+Added: As of December 31, 2022, the remaining lease term was 6.8 years.
+Added: The Company recorded expense related to the Billerica Lease in the
+Added: amount of $ 200,350 year ended December 31, 2022.
+Added: Variable lease expenses recorded by the Company were immaterial for the
+Added: year ended December 31, 2022.
+Added: During the years ended December 31, 2022, the Company made cash payments
+Added: of $ 88,366 , for amounts included in the measurement of lease liabilities.
+Added: The following table reconciles the undiscounted lease liabilities to
+Added: the total lease liabilities recognized on the consolidated balance sheet as of December 31, 2022:
+Added: Total undiscounted lease liabilities
+Added: Less effects of discounting
+Added: Total lease liabilities
+Added: Reported as of December 31, 2022:
+Added: Current portion of operating lease liability
+Added: Operating lease liability, less current portion
+Added: Total lease liabilities
Note 15 – Subsequent Events
−Removed: On January 11, 2022, the Company converted its marketable securities with
−Removed: a cost basis of $ 5,988,462 to cash equivalents.
−Removed: The Company realized a loss associated with this conversion of its marketable securities
−Removed: in the amount of $ 106,294 .
−Removed: On January 13, 2022, the Company issued 1,085,000 stock options.
−Removed: stock options expire five years from the grant date, vest over a period of three to four years, and have an exercise price of $1.73.
−Removed: On February 2, 2022, the Company entered into a new lease agreement for
−Removed: approximately 15,538 square feet of corporate office space in Billerica, Massachusetts.
−Removed: The lease has a term of 86 months, with the first
−Removed: two months of rent being $0, and subsequently escalating from $14,317 per month to $26,453 per month over the lease term.
+Added: On February 13, 2023, the Company entered into
+Added: a Securities Purchase Agreement (the “Purchase Agreement”) with institutional investors (the “Purchasers”) pursuant
+Added: to which the Company agreed to sell to the Purchasers, in a registered direct offering, an aggregate of 2,000,000 shares of common stock,
+Added: par value $ 0.00001 per share (the “Common Stock”), of the Company, at a purchase price of $ 0.90 per share of Common Stock
+Added: (the “Offering”).
+Added: On February 15, 2023, the Company closed the Offering, raising gross proceeds of $ 1,800,000 before
+Added: deducting placement agent fees and other offering expenses payable by the Company.
+Added: The Company intends to use the net proceeds of the
+Added: offering for working capital and general corporate purposes.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.